Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma
Phase: PHASE2
Conditions: Malignant Glioma
Sponsor: Annick Desjardins

CONFIDENTIAL 
The information contained in this document is regarded as confidential, and may not be disclosed to another party unless such disclosure is 
required to initiate the study, to conduct study-related activities, or to comply with national, state, or local laws and regulations.  Written 
authorization from the coordinating site and sponsor is required for disclosure otherwise. 
PT-PhI-II v04.30.14 
 
 
 
 
Phase 2 Study of Sym004 for Adult Patients with Recurrent 
Glioblastoma 
 
 
 
 
 
 
 
Sponsor: 
PI – Duke Cancer Institute 
 
Funding Source: 
Symphogen A/S 
 
Protocol Source: 
PI - Duke Cancer Institute 
 
Duke IRB#: 
Pro00063483 
 
IND# 
127275 
Principal Investigator 
Annick Desjardins, MD, FRCPC 
The Preston Robert Tisch 
Brain Tumor Center at Duke 
Room 047 Baker House 
DUMC 3624 
(919) 681-4047 
(919) 684-6674 
Annick.desjardins@duke.edu 
 
 
Sub-Investigator(s) 
Henry Friedman, MD 
Henry.friedman@duke.edu 
 
Roger McLendon, MD 
Roger.mclendon@duke.edu 
 
Katherine Peters, MD, PhD 
Katherine.peters@duke.edu 
 
Dina Randazzo, DO 
Dina.randazzo@duke.edu 
 
Gordana Vlahovic, MD, MHS 
Gordana.vlahovic@duke.edu 
Statistician 
James E. Herndon, II, PhD 
James.herndon@duke.edu 
 
Lead Study Coordinator 
Woody Massey 
Woody.massey@duke.edu 
 
Lead Regulatory Coordinator 
Elizabeth S. Miller 
Elizabeth.s.miller@duke.edu 
 
Lead Data Manager 
Eric Lipp 
Eric.lipp@duke.edu 
 
Original version: 
7/9/2015 
 
Amended version: 
03/15/2016 
 
 
05/13/2016 
 
 
07/5/2017 
 

Pro00063483:  Ph.2 Sym004 for Recurrent GBM 
Version:  07/5/2017 
 
PT-PhI-II v04.30.14 
Duke Cancer Institute 
Page 2 of 50 
CONFIDENTIAL 
 
1 TABLE OF CONTENTS 
2 
LIST OF ABBREVIATIONS ................................................................................................. 6 
3 
PROTOCOL SYNOPSIS AND RESEARCH SUMMARY .................................................. 8 
3.1 
Purpose ............................................................................................................................. 8 
3.2 
Design and Procedure....................................................................................................... 8 
3.3 
Selection of Subjects ........................................................................................................ 9 
3.4 
Data Analysis and Statistical Considerations ................................................................. 10 
4 
STUDY SCHEMA................................................................................................................ 11 
5 
BACKGROUND AND SIGNIFICANCE ............................................................................ 12 
5.1 
Study Disease ................................................................................................................. 12 
5.2 
Study Agent .................................................................................................................... 12 
5.3 
Study Purpose/Rationale ................................................................................................ 12 
6 
OBJECTIVES AND ENDPOINTS ...................................................................................... 13 
7 
INVESTIGATIONAL PLAN ............................................................................................... 14 
7.1 
Study Design .................................................................................................................. 14 
7.1.1 
Dose Modification .................................................................................................. 14 
7.1.2 
Dose Modification Post-Amendment 31 ................................................................ 14 
7.1.3 
Safety Considerations ............................................................................................. 14 
7.1.4 
Delayed Infusions for Scheduling Issues ................................................................ 15 
7.1.5 
Concomitant Medications ....................................................................................... 15 
7.1.6 
Study Drug Blinding ............................................................................................... 15 
7.1.7 
Randomization ........................................................................................................ 15 
7.1.8 
Quality of Life Assessments ................................................................................... 16 
7.2 
Rationale for Selection of Dose, Regimen, and Treatment Duration............................. 16 
7.3 
Definition of Evaluable Subjects, On Study, and End of Study .................................... 16 
7.4 
Early Study Termination ................................................................................................ 16 
8 
STUDY DRUG ..................................................................................................................... 17 
8.1 
Names, Classification, and Mechanism of Action ......................................................... 17 
8.2 
Packaging and Labeling ................................................................................................. 17 
8.3 
Supply, Receipt, and Storage ......................................................................................... 17 
8.4 
Dispensing and Preparation ............................................................................................ 17 
8.5 
Compliance and Accountability ..................................................................................... 18 
8.6 
Disposal and Destruction ............................................................................................... 18 

Pro00063483:  Ph.2 Sym004 for Recurrent GBM 
Version:  07/5/2017 
 
PT-PhI-II v04.30.14 
Duke Cancer Institute 
Page 3 of 50 
CONFIDENTIAL 
 
9 
SUBJECT ELIGIBILITY ..................................................................................................... 18 
10 SCREENING AND ON-STUDY TESTS AND PROCEDURES........................................ 19 
10.1 
Screening Examination ............................................................................................... 20 
10.2 
Run-In Period ............................................................................................................. 20 
10.3 
Treatment Period ........................................................................................................ 20 
10.4 
Re-treatment Criteria (day 1 and day 15) ................................................................... 21 
10.5 
End of Treatment ........................................................................................................ 22 
10.6 
Follow-up Period ........................................................................................................ 22 
10.7 
End of Study ............................................................................................................... 22 
10.8 
Early Withdrawal of Subject(s) .................................................................................. 22 
10.8.1 Criteria for Early Withdrawal ................................................................................. 22 
10.8.2 Follow-up Requirements for Early Withdrawal ..................................................... 23 
10.8.3 Replacement of Early Withdrawal(s)...................................................................... 23 
10.9 
Study Assessments ..................................................................................................... 23 
10.9.1 Medical History ...................................................................................................... 23 
10.9.2 Physical Exam and Neurological Assessment ........................................................ 23 
10.9.3 Radiographic Review .............................................................................................. 23 
10.9.4 Skin Toxicity Assessments ..................................................................................... 23 
10.9.5 Correlative Assessments ......................................................................................... 23 
10.9.6 Laboratory Evaluations ........................................................................................... 24 
10.9.7 Quality of Life Assessments ................................................................................... 24 
11 SAFETY MONITORING AND REPORTING.................................................................... 24 
11.1 
Adverse Events ........................................................................................................... 24 
11.1.1 Overview of Clinical Findings and side effects ...................................................... 24 
11.1.2 Reporting of AEs .................................................................................................... 25 
11.2 
Serious Adverse Events .............................................................................................. 25 
11.2.1 Reporting of SAEs to Duke Cancer Institute Safety Desk ..................................... 26 
11.2.2 Reporting to the FDA.............................................................................................. 27 
11.2.3 Safety Reporting to Symphogen Global Pharmacovigilance.................................. 27 
11.2.4 Exposure in Utero ................................................................................................... 27 
11.3 
Emergency Unblinding of Investigational Treatment ................................................ 28 
11.4 
Other Reportable Information .................................................................................... 28 
11.5 
Special Warnings and Precautions ............................................................................. 28 
11.6 
Safety Oversight Committee (SOC) ........................................................................... 28 

Pro00063483:  Ph.2 Sym004 for Recurrent GBM 
Version:  07/5/2017 
 
PT-PhI-II v04.30.14 
Duke Cancer Institute 
Page 4 of 50 
CONFIDENTIAL 
 
11.7 
External Data and Safety Monitoring Board (DSMB) ............................................... 28 
12 QUALITY CONTROL AND QUALITY ASSURANCE .................................................... 28 
12.1 
Monitoring .................................................................................................................. 28 
12.2 
Audits.......................................................................................................................... 28 
12.3 
Data Management and Processing .............................................................................. 29 
12.3.1 Case Report Forms (CRFs) ..................................................................................... 29 
12.3.2 Data Management Procedures and Data Verification ............................................. 29 
12.3.3 Study Closure .......................................................................................................... 29 
13 STATISTICAL METHODS AND DATA ANALYSIS ...................................................... 30 
13.1 
Analysis Sets............................................................................................................... 30 
13.2 
Patient Demographics and Other Baseline Characteristics ........................................ 30 
13.3 
Treatments .................................................................................................................. 30 
13.4 
Primary Objective ....................................................................................................... 30 
13.4.1 Variable ................................................................................................................... 30 
13.4.2 Statistical Hypothesis, Model, and Method of Analysis ......................................... 30 
13.4.3 Handling of missing values, censoring, and discontinuations ................................ 30 
13.5 
Secondary Objectives ................................................................................................. 31 
13.5.1 Key Secondary Objective: Safety ........................................................................... 31 
13.5.2 Other Secondary Objectives:  Response Rate and Survival ................................... 31 
13.6 
Exploratory Objectives ............................................................................................... 31 
13.7 
Interim Analysis ......................................................................................................... 32 
13.7.1 Interim Efficacy Analysis for 18 mg/kg Sym004 ................................................... 32 
13.7.2 Interim Efficacy Analysis for 24 mg/kg Sym004 ................................................... 32 
13.7.3 Skin Toxicity Monitoring among Patients Treated with 18 mg/kg Sym004 .......... 33 
13.7.4 Initial Toxicity Monitoring among Patients Treated with 24 mg/kg Sym004 ........ 33 
13.8 
Sample Size Calculation ............................................................................................. 34 
13.8.1 Sample Size Requirements for 18 mg/kg Sym004 ................................................. 34 
13.8.2 Sample Size Requirements for 24 mg/kg Sym004 ................................................. 34 
14 ADMINISTRATIVE AND ETHICAL CONSIDERATIONS ............................................. 35 
14.1 
Regulatory and Ethical Compliance ........................................................................... 35 
14.2 
DUHS Institutional Review Board and DCI Cancer Protocol Committee ................. 35 
14.3 
Informed Consent ....................................................................................................... 35 
14.4 
Study Documentation ................................................................................................. 36 
14.5 
Privacy, Confidentiality, and Data Storage ................................................................ 36 

Pro00063483:  Ph.2 Sym004 for Recurrent GBM 
Version:  07/5/2017 
 
PT-PhI-II v04.30.14 
Duke Cancer Institute 
Page 5 of 50 
CONFIDENTIAL 
 
14.6 
Data and Safety Monitoring ....................................................................................... 37 
14.7 
Protocol Amendments ................................................................................................ 37 
14.8 
Records Retention....................................................................................................... 37 
15 REFERENCES ..................................................................................................................... 38 
16 APPENDICES ...................................................................................................................... 39 
16.1 
Appendix A................................................................................................................. 39 
16.2 
Appendix B ................................................................................................................. 40 
 
 
 

Pro00063483:  Ph.2 Sym004 for Recurrent GBM 
Version:  07/5/2017 
 
PT-PhI-II v04.30.14 
Duke Cancer Institute 
Page 6 of 50 
CONFIDENTIAL 
 
2 LIST OF ABBREVIATIONS 
ADCC 
 
Antibody-Dependent Cellular Cytotoxicity 
AE 
 
Adverse Event 
AESI 
 
Adverse Event of Special Interest 
ALT 
 
Alanine Aminotransferase 
ANC 
 
Absolute Neutrophil Count 
AST 
 
Aspartate Aminotransferase  
BDI-II  
 
Beck depression inventory II 
Beta-HCG 
 
Beta Human Chorionic Gonadotropin 
BEV 
 
Bevacizumab 
CAP 
 
College of American Pathologists 
CBC 
 
Complete Blood Count 
CFR 
 
Code of Federal Regulations 
CLIA 
 
Clinical Laboratory Improvement Amendments 
CMP 
 
Comprehensive Metabolic Panel 
CPC 
 
Cancer Protocol Committee 
CR 
 
Complete Response 
CRF 
 
Case Report Form 
CT 
 
Computed Tomography 
CTCAE 
 
Common Terminology Criteria for Adverse Events 
DCI 
 
Duke Cancer Institute 
dL 
 
Deciliter 
DLP 
 
Data Lock Point 
DLT 
 
Dose Limiting Toxicity 
DSMB 
 
Data and Safety Monitoring Board 
DSMP 
 
Data and Safety Monitoring Plan 
DSUR 
 
Development Safety Update Report 
DUHS 
 
Duke University Health System 
EGFRwt 
 
Epidermal Growth Factor wild type 
EGFRvIII 
 
Epidermal Growth Factor variant type III 
ESCC 
 
Esophageal Squamous Cell Carcinoma 
FACIT-Fatigue 
Functional Assessment of Cancer Therapy-Fatigue (FACIT-Fatigue) subscale 
FACT-BR 
 
Functional Assessment of Cancer Therapy-Brain 
FDA 
 
Food and Drug Administration 
FISH 
 
Fluorescence in situ hybridization 
GBM 
 
Glioblastoma 
Gd-DTPA 
 
Gadolinium-diethylene Triamine Pentaacetic Acid 
GCP 
 
Good Clinical Practices 
GMP 
 
Good Manufacturing Practices 
H&P 
 
History & Physical Exam 
HRPP 
 
Human Research Protections Program 
HRQoL 
 
Health Related Quality of Life 
ICS 
 
Investigational Chemotherapy Service 
IHC 
 
Immunohistochemistry 
IND 
 
Investigational New Drug 
IRB 
 
Institutional Research Board 
IV (or iv) 
 
Intravenously 
KPS 
 
Karnofsky Performance Status 
MAb 
 
Monoclonal Antibody 
mCRC 
 
Metastatic Colorectal Cancer 
MedDRA    
 
Medical Dictionary for Regulatory Activities 
MG 
 
Malignant Glioma 

Pro00063483:  Ph.2 Sym004 for Recurrent GBM 
Version:  07/5/2017 
 
PT-PhI-II v04.30.14 
Duke Cancer Institute 
Page 7 of 50 
CONFIDENTIAL 
 
Mg 
 
Magnesium 
mg 
 
Milligram 
mL 
 
Milliliter 
mM 
 
Millimolar 
MRI 
 
Magnetic Resonance Imaging 
NSCLC 
 
Non-small Cell Lung Cancer 
OARC 
 
Office of Audit, Risk, and Compliance 
OS 
 
Overall Survival 
PD 
 
Progressive Disease 
PFS 
 
Progression Free Survival 
PFS6 
 
Progression Free Survival at 6 months 
p.o. 
 
per os/by mouth/orally 
PR 
 
Partial Response 
PRO 
 
Patient-Reported Outcome 
PRTBTC 
 
Preston Robert Tisch Brain Tumor Center 
PT 
 
Prothrombin Time 
PTT 
 
Partial Thromboplastin Time 
RDSPs  
 
Research Data Security Plans 
RR 
 
Response Rate 
SCCHN 
 
Squamous Cell Carcinoma of the Head and Neck 
SD 
 
Stable Disease  
SGOT 
 
Serum Glutamic Oxaloacetic Transaminase 
SOC 
 
Safety Oversight Committee 
ULN 
 
Upper Limit of Normal 
WHO 
 
World Health Organization 
XRT 
 
Radiation Therapy 
 
 

Pro00063483:  Ph.2 Sym004 for Recurrent GBM 
Version:  07/5/2017 
 
PT-PhI-II v04.30.14 
Duke Cancer Institute 
Page 8 of 50 
CONFIDENTIAL 
 
3 PROTOCOL SYNOPSIS AND RESEARCH SUMMARY 
3.1 Purpose 
The purpose of this study is to assess the activity of Sym004, a recombinant antibody mixture that specifically 
binds to EGFR, in patients diagnosed with recurrent glioblastoma whose tumor is EGFR amplified.  
 
Primary Objective: 
Assess the activity of Sym004 in patients with recurrent glioblastoma that are either non-bevacizumab  failures 
(Cohort 1) or who have previously failed bevacizumab (Cohort 2), in terms of 6-month progression-free 
survival (PFS6). 
 
Secondary Objectives: 
1. Determine the safety of Sym004 in recurrent GBM patients. 
2. Estimate response rate (RR) within the two cohorts of recurrent GBM patients. 
3. Describe overall survival (OS) within the two cohorts of recurrent GBM patients. 
 
Exploratory Objectives: 
1. Assess the impact of EGFRvIII expression on efficacy (OS and PFS) of Sym004. 
2. Describe patient-reported quality of life outcomes. 
 
Hypothesis 
This study hypothesizes that Sym004 will have greater activity in terms of PFS6 than standard treatment for 
patients with recurrent GBM. 
3.2 Design and Procedure 
This is a phase 2 study that will accrue patients with WHO grade IV recurrent malignant glioma (glioblastoma 
or gliosarcoma) in two cohorts to assess the efficacy of Sym004.  Cohort 1 will include patients who are non-
bevacizumab failures; whereas, Cohort 2 will include patients who have progressed after prior treatment with 
bevacizumab (bevacizumab-failure).  Both cohorts will accrue simultaneously, with 36 subjects in Cohort 1 and 
25 subjects in Cohort 2 (see Section 13.8 for justification of sample size).  All patients will be treated with 
Sym004, a recombinant antibody mixture that specifically binds to EGFR.  For that reason, only patients whose 
tumor is determined to be EGFR-amplified (i.e. greater than 15% of cells exhibiting  > 5 copies of EGFR loci) will 
be accrued on this study.   
 
Prior to Amendment 31, approximately 25 subjects received Sym004 at 18 mg/kg intravenously every two 
weeks.  After the approval of Amendment 31, subjects who enroll on study will receive Sym004 at 24 mg/kg 
intravenously every 2 weeks.  A total of 65 additional subjects (36 in Cohort 1 and 29 in Cohort 2) will be 
treated at the 24 mg/kg dose level.  In addition, subjects who enrolled at the 18 mg/kg dose and who 
tolerated this dose of Sym004 well (i.e. no skin toxicities ≥ grade 3) will have the option to increase their dose 
to 24 mg/kg upon approval of Amendment 31.  A treatment cycle will be 4 weeks.  The patients will have 
repeat MRIs of the brain every 8 weeks. 
 
The accrual of the first 3-6 patients at the 24 mg/kg dose level, regardless of cohort assignment, will be at a 
controlled rate for initial safety monitoring.  Details concerning this initial accrual at the 24 mg/kg dose level 
can be found in Section 13.7.4.   
 
For an exploratory objective, we will determine EGFRvIII status at baseline for all patients using archival tumor 
tissue.  If a subject has more than one source of archival or frozen tissue, each source may be requested to 
determine if EGFRvIII expression has changed over time.   

Pro00063483:  Ph.2 Sym004 for Recurrent GBM 
Version:  07/5/2017 
 
PT-PhI-II v04.30.14 
Duke Cancer Institute 
Page 9 of 50 
CONFIDENTIAL 
 
3.3 Selection of Subjects 
 
Selection of subjects will be completed by meeting the subject eligibility criteria listed in this section. 
         
Inclusion Criteria (answer must be YES to all criteria listed below) 
1. Patients must have histologically confirmed diagnosis of WHO grade 4 malignant glioma and radiographic 
evidence of recurrence or disease progression (as defined by the RANO criteria as a greater than 25% 
increase in the largest bi-dimensional product of enhancement or a new enhancing lesion, or a significant 
increase in T2/FLAIR abnormality without another co-morbid cause); 
2. Age ≥ 18 years; 
3. Karnofsky Performance Status ≥ 70%; 
4. No more than 3 prior progressions; 
5. Cohort 1 only:  Non-bevacizumab failure, i.e. either no prior bevacizumab or bevacizumab 
stable/responder, which is defined as stable for at least 6 months from prior treatment with bevacizumab 
without experiencing a bevacizumab adverse event of special interest (AESI) while on a bevacizumab-
containing regimen, such as: 
a. ≥ grade 3 hypertension not controlled by medication, hypertensive crisis, or hypertensive 
encephalopathy 
b. ≥ grade 3 proteinuria that does not resolve or nephrotic syndrome 
c. 
Any grade GI perforation 
d. ≥ grade 3 infusion-related reaction 
e. ≥ grade 3 wound healing complications 
f. 
≥ grade 3 hemorrhage or any grade CNS hemorrhage or ≥ grade 2 hemoptysis 
g. 
Any grade arterial thromboembolic event (e.g. myocardial infarction or cerebral infarction) or  ≥ 
grade 3 venous thromboembolic event 
h. Any grade posterior reversible encephalopathy syndrome (PRES) 
i. 
≥ grade 3 congestive heart failure 
j. 
≥ grade 2  non-gastrointestinal (GI) abscesses and fistulae; 
6. Cohort 2 only:  Prior progression on a bevacizumab-containing regimen (defined as having 
progressed/grown through bevacizumab by RANO criteria within 2 months of prior bevacizumab 
treatment); 
7. Pathology consistent with EGFR-amplification of tumor (i.e. greater than 15% of cells exhibiting  > 5 copies 
of EGFR loci); archival tissue may be tested for EGFR status in a separate consent; 
8. ANC ≥ 1,000 cells/µl, platelets ≥ 100,000 cells/µl, hemoglobin ≥ 9 g/dL; 
9. Adequate renal function as indicated by the following:  
a. Serum creatinine < 1.25 times upper limit of normal or calculated creatinine clearance ≥ 50 
ml/min; 
b. Urine dipstick for proteinuria < 2+ unless a 24-hour urine protein <1 g of protein is 
demonstrated; 
10. Adequate liver function as indicated by the following: 
a. Total bilirubin ≤ 1.6 mg/dL; 
b. AST/ALT ≤ 2.5 x the ULN; 
11. Magnesium ≥ 0.9 mg/dL;  
12. For subjects on corticosteroids, they must be on a stable dose for 7 days prior to anticipated start of study 
drug; 
13. No evidence of > grade 1 active CNS hemorrhage on the baseline MRI or CT scan; 
14. Signed informed consent approved by the Institutional Review Board prior to patient entry; 
15. If the patient is a sexually active female of child bearing potential whose partner is male, or if the patient 
is a sexually active male whose partner is a female of child bearing potential, the patient must agree to 
use appropriate contraceptive measures for the duration of the treatment of the tumor and for 6 months 
afterwards as stated in the informed consent.  Female patients of child bearing potential must have a 
negative serum pregnancy test within 48 hours of starting study treatment; 

Pro00063483:  Ph.2 Sym004 for Recurrent GBM 
Version:  07/5/2017 
 
PT-PhI-II v04.30.14 
Duke Cancer Institute 
Page 10 of 50 
CONFIDENTIAL 
 
16. Fertile male subjects must agree to use a medically acceptable contraceptive method (allowed methods 
of birth control include vasectomy or condom with spermicide) during the trial and for a period of at least 
6 months following the last administration of trial drugs. 
 
Exclusion Criteria (answer must be NO to all criteria listed below): 
1. Pregnancy or breastfeeding; 
2. Prior treatment with EGFR-targeted therapy, including, but not limited to, the following examples:  
Gilotrif® (afatinib),Tarceva® (erlotinib), Erbitux® (cetuximab), Iressa™ (gefitinib), Vectibix® 
(panitumumab), Caprelsa® (vandetanib), Tykerb® (lapatinib), CDX110, D2C7-immunotoxin);  
3. Active infection requiring intravenous antibiotics within 7 days before enrollment; 
4. Prior, unrelated malignancy requiring curent active treatment with the exception of cervical carcinoma in 
situ and adequately treated basal cell or squamous cell carcinoma of the skin; 
5. Less than 12 weeks from radiation therapy, unless progressive disease outside of the radiation field or 2 
progressive scans at least 4 weeks apart or histopathologic confirmation; 
6. Treated with immunotherapeutic agents, vaccines, or Mab therapy within 4 weeks before enrollment, 
unless the patient has recovered from the expected toxic effects of such therapy; 
7. Treated with alkylating agents within 4 weeks (6 weeks for nitrosoureas) before enrollment or treated 
within 1 week before enrollment with daily or metronomic chemotherapy, unless the patient has 
recovered from the expected toxic effects of such therapy to their baseline or to grade 1; 
8. Prior treatment (non-alkylating agents) within 2 weeks before enrollment, unless the patient has 
recovered from the expected toxic effects of such therapy;  
9. Known hypersensitivity reactions to any of the components of Sym004; 
10. Known current drug abuse or alcohol abuse; 
11. Known Human Immunodeficiency Virus (HIV), Hepatitis B, or Hepatitis C infection. Testing is not required 
as part of this study. 
3.4 Data Analysis and Statistical Considerations 
Kaplan-Meier curves will be generated to describe the PFS and OS experience of patients enrolled on this 
protocol within each cohort and dose level.  Progression-free survival (PFS) is defined as the time interval 
between initiation of protocol treatment and either disease progression or death.  If the patient is alive and 
progression-free, PFS will be censored at the date last known alive.  Overall survival (OS) is defined as the time 
interval between initiation of protocol treatment and death, or date of last follow-up if alive.  Estimates with 
confidence intervals will be generated for median PFS and OS, as well as 2 month intervals for PFS for the first 
year (2, 4, 6, etc..) and 6  month intervals for OS for the first 2 years (6, 12, 18, 24) from the time the subject 
goes on  study. 
 
Radiographic response rate will be estimated as the proportion of treated patients with a complete or partial 
response (see Appendix B).  An exact binomial confidence interval will be generated. 
 
For each type of toxicity, the maximum grade experienced by each patient will be summarized with frequency 
distributions within each cohort and dose level.  Two adverse experience tabulations will be generated, one 
that includes all toxicities regardless of attribution, and one that includes only toxicities that are possibly, 
probably, and definitely related to Sym004 treatment. 
 
Cox proportional hazards model will be used to examine the association between EGFRvIII expression and PFS 
and OS. 
 
At the 18 mg/kg dose level, interim analyses will be conducted after 19 total patients across both cohorts have 
been treated with Sym004.  These interim analyses will focus on the prevalence of skin toxicities. 
 
With each cohort of the study at the 24 mg/kg dose level, the study is designed as a two-stage study to assess 
6-month PFS.  After the initial stage, interim futility analyses will be conducted.

Pro00063483:  Ph.2 Sym004 for Recurrent GBM 
Version:  07/5/2017 
 
PT-PhI-II v04.30.14 
Duke Cancer Institute 
Page 11 of 50 
CONFIDENTIAL 
 
4 STUDY SCHEMA 
 
 
 
 
 
 
 
 
 
 
Cohort 1:  Patients diagnosed with 
WHO grade IV recurrent MG who are 
non-bevacizumab failures  
Cohort 2: Patients diagnosed with WHO 
grade IV recurrent MG who have failed 
treatment with  bevacizumab 
Sym004:  18 
mg/kg IV every 
two weeks.  
Following 
Amendment 
31, increased 
to 24 mg/kg,  
provided 
tolerability is 
demonstrated. 
CR, PR, SD 
PD, Toxicity 
Continue on Sym004 
until complete planned 
treatment regimen, PD 
or unacceptable 
toxicity. 
Discontinue protocol 
treatment 
Follow 1 year 
 1 year  

Pro00063483:  Ph.2 Sym004 for Recurrent GBM 
Version:  07/5/2017 
 
PT-PhI-II v04.30.14 
Duke Cancer Institute 
Page 12 of 50 
CONFIDENTIAL 
 
5 BACKGROUND AND SIGNIFICANCE 
5.1 Study Disease 
There is an unmet clinical need for the therapy of malignant gliomas with a median survival of <20 months 
despite available therapies.  The current standard of care is radiation therapy with daily temozolomide followed 
by 6 cycles of temozolomide.1   
 
Glioblastoma (GBM) is a highly angiogenic, aggressive malignant primary brain cancer; it is the most common 
and aggressive type of primary brain tumor in humans.  It accounts for 52% of all primary brain tumor cases and 
20% of all intracranial tumors.  The median progression-free survival for patients treated with surgery followed 
by radiation and temozolomide is under 7 months.  Median overall survival is under 15 months.  No effective 
therapy exists following recurrence.2  Few cytotoxic drugs are available for the treatment of GBM because of the 
difficulty of crossing the blood-brain barrier.  Temozolomide, an alkylating agent, is the current standard of care 
3,4 in combination with surgical resection and radiation therapy.5  Recurrent GBM has an initial response to 
temozolomide therapy.  Although different dosing regimens have been tried to reduce the tumor burden, GBM 
loses sensitivity to temozolomide.5  Overall survival is not improved and tumor progression results.4  Effective 
treatment remains an unmet medical need.   
5.2 Study Agent 
Sym004 is a recombinant antibody mixture that binds specifically to the epidermal growth factor receptor 
(EGFR).  Sym004 contains two mouse-human chimeric IgG1 monoclonal antibodies, futuximab and 
modotuximab, in a 1:1 ratio. Per the Investigator’s Brochure (v. 2.0, 22-Jan-2015), the antibodies bind to non-
overlapping epitopes on the extracellular domain III of EGFR.  The binding induces a distinct mechanism of action 
that is dependent on the presence of both antibodies and translates into a superior anti-cancer activity 
compared to monoclonal reference antibodies.  This was demonstrated both in vitro using human cancer cell 
lines and in vivo using EGFR-dependent tumor xenografts.  Sym004 induces highly efficient internalization of 
EGFR on cancer cells and degradation, which results in inhibition of cancer cell growth.  Sym004 is being 
investigated for the treatment of subjects with advanced metastatic colorectal cancer (mCRC), for the treatment 
of recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN), for the treatment of non-small 
cell lung cancer (NSCLC), and for the treatment of esophageal squamous cell carcinoma (ESCC) in Japanese 
subjects. 
 
Studies have shown that Sym004 is superior at inhibiting EGFR activity compared to cetuximab and/or 
panitumumab (used as reference antibodies) in vitro through a mechanism of action that is dependent on 
binding of both antibodies.  Furthermore, the activity of Sym004 was investigated in several xenograft tumor 
models in mice and compared to cetuximab and/or panitumumab.  In all models, Sym004 was superior or as 
efficient as these reference antibodies. 
 
Five clinical trials have been completed with Sym004 and 2 clinical trials are currently ongoing ongoing according 
to the most resent Symphogen Development Safety Update Report (report dated 13 Mar 2017).  Sym004 shows 
early signs of promising activity in the trials conducted so far.  Sym004 was shown to induce tumor shrinkage in 
subjects resistant to combination treatment with platinum-based chemotherapy and cetuximab in 
recurrent/metastatic SCCHN.  The median OS with Sym004 of around 5 months is in the range of the reported 
median OS in less heavily pre-treated (cetuximab-naïve), platinum-resistant recurrent/metastatic SCCHN 
subjects treated with compounds such as methotrexate or cetuximab.  In subjects with mCRC and acquired 
resistance to cetuximab, Sym004 showed promising activity as it was able to induce tumor shrinkage in about 30-
48% of subjects including several cases of partial response. 
5.3 Study Purpose/Rationale 
Glioblastomas (GBMs) are highly aggressive and lethal malignant brain tumors.  The human epidermal growth 
factor receptor (EGFR; HER-1) is a transmembrane receptor tyrosine kinase. It is an attractive therapeutic target 

Pro00063483:  Ph.2 Sym004 for Recurrent GBM 
Version:  07/5/2017 
 
PT-PhI-II v04.30.14 
Duke Cancer Institute 
Page 13 of 50 
CONFIDENTIAL 
 
for based on its role as an oncogenic driver. EGFR is amplified in 35-40% of primary GBM tumors.6,7 
Approximately 50% of EGFR-amplified GBMs express EGFRvIII,8 a constitutively active, ligand-independent 
mutant receptor with impaired down-regulation. So far, most efforts at targeting EGFR have revolved around the 
utilization of tyrosine kinase inhibitors, which have almost invariably failed to show efficacy in WHO grade IV 
malignant glioma patients.  
 
Sym004 is a recombinant antibody mixture which binds specifically to EGFR. Sym004 contains 2 mouse-human 
chimeric IgG1 monoclonal antibodies (Mabs), futuximab and modotuximab. The antibodies bind to non-
overlapping epitopes on the extracellular domain III of EGFR. Sym004 is not only designed to block ligand 
binding, receptor activation and downstream signaling but also elicits effective removal of the EGFR receptors 
from the cancer cell surface by inducing EGFR internalization and degradation. In addition, unlike the single 
monoclonal anti-EGFR antibodies which only mediate antibody-dependent cellular cytotoxicity (ADCC), Sym004 
mediates both ADCC and complement-mediated cytotoxicity against EGFR-positive tumor targets.  The activity of 
Sym004 was investigated in several xenograft tumor models in mice and compared to cetuximab and/or 
panitumumab. In all models, Sym004 was either superior to or as efficient as these reference antibodies. Three 
clinical trials have been completed with Sym004 as a single agent in subjects with recurrent advanced solid 
tumors (Sym004-01, Sym004-02, and Sym004-06). Sym004 shows signs of promising activity in both trials 
conducted so far. Skin toxicities were the most frequently reported AEs, seen in 80-97% of subjects. 
 
Given the dire need for new therapies for recurrent GBM, particularly after bevacizumab-failure, the proposed 
clinical trial is an important step in the field of neuro-oncology. To assure that the appropriate patient population 
will be enrolled on study, only recurrent WHO grade IV malignant glioma patients with known EGFR amplification 
as defined in the eligibility criteria (at diagnosis or at recurrence) will be eligible. 
6 OBJECTIVES AND ENDPOINTS 
 
Objective 
Endpoint 
Analysis 
Primary 
Assess the activity of Sym004 in 
patients with recurrent glioblastoma 
that are either non-bevacizumab 
failures (Cohort 1) or who have 
previously failed bevacizumab 
(Cohort 2) 
The percentage of subjects who remain alive 
and progression free at 6 months (PFS6) at 
each dose level 
See Section 13.4 
Key Secondary 
Determine the safety of Sym004 in 
recurrent GBM patients 
The proportion of patients with grade 3, 4, or 
5 treatment-related adverse events at each 
dose level 
See Section 13.5.1 
Other Secondary 
Estimate response rate (RR)  within 
two cohorts of recurrent GBM 
patients 
Proportion of treated patients with a 
complete or partial response at each dose 
level 
See Section 13.5.2 
Other Secondary 
Describe overall survival (OS) within 
two cohorts of recurrent GBM 
patients 
Median OS at each dose level 
See Section 13.5.2 
Exploratory 
Assess the impact of EGFRvIII 
expression on efficacy (OS and PFS) 
of Sym004 
Median OS and PFS within subgroups of 
patients defined by EGFRvIII expression and 
dose level 
See Section 13.6 
Exploratory 
Describe patient-reported quality of 
life outcomes (PROs) 
Mean change from baseline in each Patient-
Reported Outcome (PRO) subscale within 
each Cohort and dose level 
See Section 13.6 
 
 
 
 
 
 
 

Pro00063483:  Ph.2 Sym004 for Recurrent GBM 
Version:  07/5/2017 
 
PT-PhI-II v04.30.14 
Duke Cancer Institute 
Page 14 of 50 
CONFIDENTIAL 
 
7 INVESTIGATIONAL PLAN 
7.1 Study Design 
This is a phase 2 study that will accrue patients with WHO grade IV recurrent malignant glioma (glioblastoma or 
gliosarcoma) in two cohorts to assess the efficacy of Sym004.  Cohort 1 will include patients who are non-
bevacizumab failures; whereas, Cohort 2 will include patients who have progressed after prior treatment with 
bevacizumab (bevacizumab-failure).  Both cohorts will accrue simultaneously, with a goal of 36 subjects in 
Cohort 1 and 25 subjects in Cohort 2 (see Section 13.8 for justification of sample size).  All patients will be 
treated with Sym004, a recombinant antibody mixture that specifically binds to EGFR.  For that reason, only 
patients whose tumor is determined to be EGFR-amplified will be accrued on this study.    
 
Prior to Amendment 31, approximately 25 subjects received Sym004 at 18 mg/kg intravenously every 2 weeks.  
After the approval of Amendment 31, subjects who enroll on study will receive 24 mg/kg intravenously every 2 
weeks.  A maximum of 65 additional subjects (36 in Cohort 1 and 29 in Cohort 2) will be treated at the 24 mg/kg 
dose level.  In addition, subjects who enrolled at the 18 mg/kg dose and who tolerated this dose of Sym004 well 
(i.e. no skin toxicities ≥ grade 3) will have the option to increase their dose to 24 mg/kg upon approval of 
Amendment 31.  A treatment cycle will be 4 weeks.  The patients will have repeat MRIs of the brain every 8 
weeks.  Subjects with CR, PR, or stable disease may continue on study as long there is no evidence of disease 
progression or toxicities as described in Section 10.8.1. 
 
The accrual of the first 3-6 patients at the 24 mg/kg dose level, regardless of cohort assignment, will be at a 
controlled rate for initial safety monitoring.  Details concerning this initial accrual at the 24 mg/kg dose level can 
be found in Section 13.7.4. 
 
For an exploratory objective, we will determine EGFRvIII status at baseline for all patients using archival tumor 
tissue.  If a subject has more than one source of archival or frozen tissue, each source may be requested to 
determine if EGFRvIII expression has changed over time.   
7.1.1 Dose Modification 
For subjects receiving 18 mg/kg, the dose of Sym004 may be reduced by up to two dose levels, if the 
subject experiences grade 3-4 non-hematologic toxicities secondary to Sym004, e.g. skin toxicities, 
electrolyte disturbances, and gastrointestinal symptoms, or grade 4 neutropenia or thrombocytopenia.  
Following the initial dose of 18 mg/kg every 2 weeks, if the subject needs to have their dose of Sym004 
reduced due to an aforementioned toxicity, then their next dose will be 15 mg/kg every 2 weeks.  If 
another reduction in dose is necessary, the subsequent dose will be 12 mg/kg every 2 weeks.  If dose 
reduction is required more than two times, the patient will be removed from the study.  
7.1.2 Dose Modification Post-Amendment 31 
For subjects receiving 24 mg/kg, the dose of Sym004 may be reduced by up to two dose levels, if the 
subject experiences grade 3-4 non-hematologic toxicities secondary to Sym004, e.g. skin toxicities, 
electrolyte disturbances, and gastrointestinal symptoms, infusion-related reactions, or grade 4 
neutropenia or thrombocytopenia.  Exceptions to this dose reduction include grade 3 nausea, vomiting, 
diarrhea or fatigue lasting ≤ 5 days with supportive care or grade 3 asymptomatic electrolyte 
abnormalities.  Following the initial dose of 24 mg/kg every 2 weeks, if the subject needs to have their 
dose of Sym004 reduced due to an aforementioned toxicity, then their next dose will be 18 mg/kg every 2 
weeks.  If another reduction in dose is necessary, the subsequent dose will be 15 mg/kg every 2 weeks.  If 
dose reduction is required more than two times, the patient will be removed from the study. 
7.1.3 Safety Considerations 
According to the Sym004 Investigator’s Brochure (v. 8.0, 13-Mar-2017), skin toxicities have been the most 
frequently reported AEs.  To date (20 Jan 2017), approximately 380 subjects with solid tumors, including 

Pro00063483:  Ph.2 Sym004 for Recurrent GBM 
Version:  07/5/2017 
 
PT-PhI-II v04.30.14 
Duke Cancer Institute 
Page 15 of 50 
CONFIDENTIAL 
 
subjects with recurrent/metastatic SCCHN, mCRC, ESCC and NSCLC, have been treated with Sym004 in 
weekly doses of up to 12 mg/kg and in doses every other week of up to 18 mg/kg in ongoing Symphogen-
sponsored studies.  Anti-EGFR related skin toxicities (including rash, pruritus, skin fissures, dry skin, 
erythema, and paronychia) have been observed in more than 90% of subjects in the completed and 
ongoing clinical trials.  In subjects who had previously received anti-EGFR mAb therapy, Grade 3 skin 
toxicities were frequently reported; 50-69% of subjects at a dose of 9 or 12 mg/kg weekly (Sym004-01 
Parts B and C and Sym004-02) and 33.3% and 41.2% of subjects at dose levels of 12 mg/kg and 18 mg/kg, 
respectively, every other week (Sym004-01 Parts D and E). 
 
Other adverse events (AEs) associated with anti-EGFR mAbs, such as electrolyte disturbances (in particular 
hypomagnesemia), mucositis, and diarrhea were also frequently observed in the completed and ongoing 
trials.   In clinical trials for which AE data are available (Sym004-01-Parts A, B, C, D, E, Sym004-02, and EMR 
200637-001-Part A) hypomagnesemia was reported in 54-77% of subjects, and 0-38% of subjects 
experienced Grade 3 or 4 hypomagnesemia. In the Sym004-01 and Sym004-02 clinical trials, events of 
hypomagnesemia also represented the majority of serious adverse events (SAEs) that were considered to 
be related to Sym004 therapy.  Serious clinical complications of hypomagnesemia have not been 
observed.  Mucositis was observed in up to 40% of subjects, but the number of subjects experiencing 
Grade 3 mucositis was low (1 subject).  Diarrhea has been reported in up to 59% of subjects; and ≤ 10% of 
subjects experienced Grade 3 diarrhea.  Infusion related reactions have also been observed. 
 
Therefore, subjects will be assessed at each clinic visit, beginning with Cycle 1:Day 15, for skin toxicities 
according to Duke Medicine’s “Guidelines for Management of Cutaneous Toxicity for Patients Receiving 
Epidermal Growth Factor Receptors” (see Appendix A).  Patients will be instructed to call if the rash is 
painful or interfering with daily functioning.  In all ongoing clinical trials, premedication with 
glucocorticosteroids and antihistamines prior to Sym004 infusion is required.    Pre-medications in the 
current study are described in Section 7.1.5 below.  Supplemental guidelines on grading and management 
of skin toxicities due to Sym004 have been provided by Symphogen in their “Skin Management Booklet.”  
This booklet has been used on other Sym 004trials and has been provided as a helpful tool for providers. 
7.1.4 Delayed Infusions for Scheduling Issues 
A delayed infusion of Sym004, due to scheduling issues, may be re-scheduled within the following 4 days.   
7.1.5 Concomitant Medications 
Skin toxicities will be treated according to Duke Medicine’s “Guidelines for Management of Cutaneous 
Toxicity for Patients Receiving Epidermal Growth Factor Receptors” (see Appendix A), in conjunction with 
Symphogen’s “Skin Management Booklet” for Sym004.  In the current study, subjects should receive the 
following premedications, according to institutional guidelines and the judgement of the treating 
physician:  diphenhydramine 50 mg IV and a glucocorticoid steroid, such as hydrocortisone 100 mg IV, 30-
60 minutes prior to the first dose.  Premedication should be administered for subsequent doses based 
upon clinical judgment and presence/severity of prior need. 
 
Hypomagnesaemia, mucosal inflammation, and diarrhea will be treated according to institutional 
guidelines and the treating physician’s discretion. 
7.1.6 Study Drug Blinding 
Not applicable. 
7.1.7 Randomization 
Not applicable. 

Pro00063483:  Ph.2 Sym004 for Recurrent GBM 
Version:  07/5/2017 
 
PT-PhI-II v04.30.14 
Duke Cancer Institute 
Page 16 of 50 
CONFIDENTIAL 
 
7.1.8 Quality of Life Assessments 
Quality of Life will be assessed using standardized and validated questionnaires.  These questionnaires 
include Functional Assessment of Cancer Therapy-Brain (FACT-BR) scale,9 Functional Assessment of Cancer 
Therapy-Fatigue (FACIT-Fatigue) subscale, version 4,10 and  Beck depression inventory II (BDI-II).11   
 
All quality of life assessments will be completed at baseline, prior to the start of every other cycle 
beginning with Cycle 3, and at the end of the study.  These assessments should be completed prior to 
other study-related evaluations at study visits, if at all possible.  If the subject is found to have progressive 
disease prior to beginning an even-numbered cycle, when HRQoL assessments are not conducted, they 
may complete these assessments at any time during the clinic visit. 
7.2 Rationale for Selection of Dose, Regimen, and Treatment Duration 
Per the Sym004 Investigator’s Brochure (v. 7.0, 10-Mar-2017), seven clinical trials have been conducted with 
Sym004, 3 clinical trials have been completed, and 4 clinical trials are ongoing.  More than 365 patients with solid 
tumors have been exposed to Sym004 thus far in weekly doses of up to 12 mg/kg and in doses every other week 
of up to 18 mg/kg.  Results thus far indicate that the 18 mg/kg every other week dosing results in substantially 
less issues with skin toxicity than other dosing/scheduling regimens (see Section 7.1.3 for details regarding the 
frequency of skin toxicities experienced with the Sym004 dosing regimens in ongoing clinical trials).  A total of 17 
patients have received 18 mg/kg every other week in Part E of the Sym004-01 trial.   
 
In the current trial, interim analysis occurred after 19 patients were treated.  After those 19 patients were 
treated at 18 mg/kg, it was observed that only two patients experienced grade 3 skin toxicity. Of those 19 
patients, 16 patients came off study due to disease progression before reaching 6 months and only one patient 
completed six months of therapy before experiencing disease progression. Multiple EGFR-directed therapy trials 
have previously reported that patients who experience EGFR-directed therapy side effects (e.g. skin toxicity) are 
those who receive the greatest therapeutic benefit from this type of therapy.  Hence, it is hypothesized that 
increasing the dose of Sym004 to 24 mg/kg in the current study might increase the frequency of skin toxicity, but 
also improve the overall tumor response to the therapy.  Skin toxicities will continue to be managed according to 
Duke Medicine’s “Guidelines for Management of Cutaneous Toxicity for Patients Receiving Epidermal Growth 
Factor Receptors” (see Appendix A), along with pre-medications described in Section 7.1.3. 
7.3 Definition of Evaluable Subjects, On Study, and End of Study 
Safety and efficacy analyses will include all patients who received any Sym004 treatment. 
 
Patients will be considered “on study” once they have signed the informed consent form, and will continue to be 
considered “on study” as long as they are receiving study-related treatment or are undergoing study-related 
follow-up tests and procedures.  If a patient who signs the informed consent form does not meet the eligibility 
criteria of the study, he or she will come off study as a “screen failure.”  Patients who sign informed consent,  are 
eligible to participate, and receive study-related treatment are considered enrolled in the study.  Subjects will be 
considered “off study” when they are no longer receiving study-related treatment and are no longer having 
study-related follow-up tests and procedures.  Once “off study,” subjects who are not screen failures will be 
followed for progression (for patients who came off study prior to disease progression) and survival status (all 
patients) for at least 1 year, if possible.   
7.4 Early Study Termination 
This study can be terminated at any time for any reason by the PI-sponsor.  If this occurs, all subjects on study 
will be notified as soon as possible.  Additional procedures and/or follow up should occur in accordance with 
Section 10.8, which describes procedures and process for prematurely withdrawn patients. 

Pro00063483:  Ph.2 Sym004 for Recurrent GBM 
Version:  07/5/2017 
 
PT-PhI-II v04.30.14 
Duke Cancer Institute 
Page 17 of 50 
CONFIDENTIAL 
 
8 STUDY DRUG 
8.1 Names, Classification, and Mechanism of Action 
Sym004 is a 1:1 mixture of the 2 mouse-human chimeric immunoglobulin (Ig) G1 monoclonal antibodies (mAbs), 
futuximab and modotuximab.  The antibodies bind to non-overlapping epitopes on the extracellular domain III of 
EGFR.  Each antibody is manufactured separately as an individual drug substance.  The 2 drug substances are the 
same with respect to formulation and protein concentration. Sym004 is prepared and released as a mixture of 
the antibodies. 
8.2 Packaging and Labeling 
The Sym004 drug product is a sterile liquid product containing 5.0 mg/mL Sym004 active ingredient, filled in 30 
mL USP Type 1 glass vials with a FluroTec®-coated halobutyl/butyl rubber stoppers and secured with caps with 
flip-off seals .  For clinical trial administration, each vial of Sym004 drug product has an extractable volume of 30 
mL. 
 
The composition, as described in the Investigator’s Brochure (v. 7.0, 10-Mar-2016), is presented below: 
 
Name of ingredient 
Quantity (per mL) Function 
Grade 
Futuximab 
2.5 mg 
Active pharmaceutical 
ingredient 
In-house 
Modotuximab 
2.5 mg 
Active pharmaceutical 
ingredient 
In-house 
Inactive ingredients 
Tri-sodium citrate dehydrate 
2.38 mg 
Buffer component 
Ph.Eur., USP 
Citric acid monohydrate 
0.37 mg 
Buffer component 
Ph.Eur., USP 
Sodium chloride 
8.77 mg 
Tonicity adjustment 
Ph.Eur., USP 
Sodium hydroxide 
~ 0.12 mga 
pH adjustment 
Ph.Eur., USP 
Polysorbate 20 
0.5 mg 
Stabilizer 
Ph.Eur., USP 
Water for injection 
q.s. 1.0 mL 
Solvent 
Ph.Eur., USP 
Ph. Eur=European Pharmacopoeia; USP=United States Pharmacopoeia. 
a Typical amount required for pH adjustment. 
 
Packaging, labeling, and distribution to site of the Sym004 in 30 mL vials is performed at Catalent Pharma 
Solutions, United Kingdom. Packaging and labeling will be in accordance with applicable local requirement and 
applicable GMP guidelines. 
8.3 Supply, Receipt, and Storage 
Sym004 will be packaged, labeled and supplied for clinical use by Catalent Pharma Solutions, UK.  Sym004 is 
intended for single use and should be stored between 2°C and 8°C (36°-46°F) and must not be frozen.  The vial 
should be kept in the outer carton.  Sym004 will be supplied in cartons containing 10 vials.   
 
Sym004 will be filtered using an inline filter (0.2μm) during infusion. The product must be protected from direct 
sunlight and must not be frozen.  The diluted infusion solution of Sym004 does not contain preservatives  and 
must be used within 8 hours of preparation.  Preparation of the infusion bag must be done immediately before 
the infusion is initiated, under aseptic conditions.   
8.4 Dispensing and Preparation 
Sym004 will be prepared and dispensed by the Duke Investigational Chemotherapy Service (ICS).  The dose of 
Sym004 is determined by the subject’s body weight prior to each infusion.   
 
Materials needed for preparation of Sym004 infusion bags: 

Pro00063483:  Ph.2 Sym004 for Recurrent GBM 
Version:  07/5/2017 
 
PT-PhI-II v04.30.14 
Duke Cancer Institute 
Page 18 of 50 
CONFIDENTIAL 
 
• 
1000ml, 0.9% NaCl non–PVC infusion bags (see Table below for selection of infusion bag at different doses)  
• 
Sym004 vials  
• 
Needles  
• 
Syringes  
• 
Pre-printed drug bag labels (provided by Duke ICS)  
• 
Polyethylene lined tubing having the 0.2 or 0.22 μm filter as part of the path or as an extension 
 
Infusion bag containing 0.9% NaCl used for the different dose levels 
Dose Level (mg/kg) 
Infusion Bag 
12 
1000 mL 
15 
1000 mL 
18 
1000 mL 
24 
1000 mL 
 
Preparation of Sym004 infusion bags: 
• 
Sym004 is diluted into infusion bags containing 1000 mL 0.9 % NaCl.   
• 
Remove the calculated volume of 0.9% NaCl from the infusion bag. 
• 
Gently mix the vials by swirling clockwise – anticlockwise – clockwise for 10-15 seconds.  
• 
Draw the calculated amount of Sym004 from an appropriate number of the Sym004 vials and inject it into 
the bag.  
• 
Invert the bag slowly 3 times. 
• 
Label the bag with the completed preprinted label, including the exact time of preparation.  
• 
After Sym004 has been diluted in 0.9% NaCl, it can be kept at room temperature for up to 8 hours.  
• 
Connect the tubing having the 0.2 or 0.22 μm filter as part of the path to the bag.  Filtration only occurs at 
this step of the Sym004 administration. 
• 
Start the infusion at 75 mL/hour.  The infusion rate may be doubled every 30 minutes as tolerated, at the 
investigator’s discretion.  The maximum infusion rate is not to exceed 10 mg/min (600 mg/hr). 
8.5 Compliance and Accountability 
Drug accountability records will be maintained for all clinical trial supplies.  All empty and partially used clinical 
trial supplies will be destroyed in accordance with the institution’s requirements for a cytotoxic agent.  ICS will 
maintain detailed documentation of the number and identification of vials which are destroyed, and copies of 
these documents will be provided to Symphogen. 
8.6 Disposal and Destruction 
Disposition of all unused drug product will be carried out according to instructions provided by Symphogen at 
the end of the study after drug accountability is performed. 
9 SUBJECT ELIGIBILITY 
Please see Section 3.3 for a complete list of inclusion and exclusion criteria. 

Pro00063483:  Ph.2 Sym004 for Recurrent GBM 
Version:  07/5/2017 
 
PT-PhI-II v04.30.14 
Duke Cancer Institute 
Page 19 of 50 
CONFIDENTIAL 
 
10 SCREENING AND ON-STUDY TESTS AND PROCEDURES 
 
Time Points 
 
 
Cycle 1 
Cycle 2 
Cycle 3 
Cycle 4… 
 
Evaluation 
Screening a 
Day 1 
Day 15 
Day 1 
Day 15 
Day 1 
Day 15 
Day 1 
Day 15 
End of 
Treatment 
Informed consent 
X 
 
 
 
 
 
 
 
 
 
Determination of EGFR 
amplification b 
X 
 
 
 
 
 
 
 
 
 
History and complete 
physical exam, including 
full neurologic exam & 
KPS  
X 
 
 
 
 
X 
 
 
 
X 
Interval history and brief 
physical exam 
 
X c 
X 
X 
X 
 
X 
X 
X 
 
Vital signs, including 
blood pressure and 
weight; calculate BMI d 
X 
X c 
X 
X 
X 
X 
X 
X 
X 
X 
CBC with differential e 
X 
 
X 
X 
X 
X 
X 
X 
X 
X 
CMP + Mg e 
X 
 
X 
X 
X 
X 
X 
X 
X 
X 
Urinalysis 
X 
 
 
 
 
 
 
 
 
 
Beta-HCG, if applicable, 
within 48 hours prior to 
start of study treatment, 
if contraception not 
initiated at time of 
negative test result prior 
to that time   
X 
 
 
 
 
 
 
 
 
 
MRI of the brain f 
X 
 
 
 
 
X 
 
 
 
X 
Determination of EGFRvIII 
from archival tumor 
tissue g 
X 
 
 
 
 
 
 
 
 
 
Quality of life 
measurements h 
X 
 
 
 
 
X 
 
 
 
X 
Skin toxicity assessment i 
X 
 
X 
X 
X 
X 
X 
X 
X 
X 
Toxicity assessment 
 
Ongoing 
Pre-medication j 
 
X 
 
 
 
 
 
 
 
 
Sym004 infusion 
 
X 
X 
X 
X 
X 
X 
X 
X 
 
a Within 2 weeks prior to first dose of Sym004.  Some tests and procedures (as noted) are for a baseline only, not for eligibility.  
b Determination of EGFR amplification may be taken from the original pathology diagnosis or maybe be tested from archival tissue as a 
part of screening by FISH (separate consent).   
c Interval history with brief physical exam, vital signs, blood pressure, and weight do not need to be repeated if the screening exam and 
vitals occurred within 3 days of Day 1. 
dBMI must be calculated before every infusion.   
e Every 2 weeks, beginning with Cycle 1:Day 15. 
f MRIs will be obtained every 8 weeks (i.e. every other cycle), prior to the start of the next cycle. 
g EGFRvIII expression will be determined at baseline using archival tumor tissue; however, if a subject has more than one source of 
archival or frozen tissue, each source may be requested to determine if EGFRvIII expression has changed over time.  EGFRvIII expression 
will be determined using IHC by the Duke Department of Pathology if not previously obtained.    
h All quality of life assessments will be completed at baseline, prior to the start of every other cycle beginning with Cycle 3, and at the 
end of the study.  These assessments should be completed prior to other study-related evaluations at study visits, if at all possible.  If 
the subject is found to have progressive disease prior to beginning an even-numbered cycle, when HRQoL assessments are not 
conducted, they may complete these assessments at any time during the clinic visit. 
i Skin toxicity will be evaluated at baseline and at each clinic visit, beginning with Cycle 1 Day 15, and patients will be instructed to call if 
the rash is painful or interfering with daily functioning.  If a rash is identified, it should be treated according to Duke Medicine’s 
“Guidelines for Management of Cutaneous Toxicity for Patients Receiving Epidermal Growth Factor Receptors” (see Appendix A). 
j Pre-medication should include diphenhydramine 50 mg IV and a glucocorticoid steroid, such as hydrocortisone 100 mg IV, 30-60 
minutes prior to the first dose.  Premedication should be administered for subsequent doses based upon clinical judgment and 
presence/severity of prior need. 

Pro00063483:  Ph.2 Sym004 for Recurrent GBM 
Version:  07/5/2017 
 
PT-PhI-II v04.30.14 
Duke Cancer Institute 
Page 20 of 50 
CONFIDENTIAL 
 
10.1 Screening Examination 
If a candidate subject does not have EGFR status in his or her medical records, EGFR and EGFRvIII status may be 
tested from that patient’s archival biopsy.  The subject must sign a tissue screening consent before this can take 
place. 
 
The screening examinations and procedures will take place within 2 weeks of starting study drug treatment.  An 
informed consent must be signed by the patient before any research-related screening procedure takes place.   
 
If screening occurs within 3 days of first study drug infusion, the screening tests can be used as Cycle 1 Day 1 
examinations.  Pre-treatment evaluations to determine eligibility are listed in the schema above and include the 
following:   
• 
History and full physical exam, including a full neurologic assessment and KPS, two weeks prior to starting 
treatment  
• 
Vital signs, including blood pressure and weight 
• 
CBC with differential, CMP+Mg, Beta-HCG if appropriate (within 48 hours of beginning study drug if 
contraception not initiated at time of negative test result prior to that time)  
• 
Urinalysis 
• 
Baseline MRI of the brain 2 weeks prior to starting treatment 
• 
Determination of EGFRvIII from archival tumor tissue  
• 
Skin assessment, as a baseline measurement 
• 
Quality of life measurements, as a baseline measurement 
• 
Determination of EGFRvIII amplification 
 
If a subject is found to be ineligible to participate in the study, minimal records regarding the subject and the 
reason for screen failure will be retained in the study database. 
10.2 Run-In Period 
Not applicable. 
10.3 Treatment Period 
Please also see the schema above for an itemized list of evaluations in this study and their corresponding time 
points. 
 
Cycle 1, Day 1  
• 
Interval history and brief physical exam 
• 
Vital signs, including blood pressure and weight (Calculate BMI) 
• 
Toxicity assessment (continuous throughout the study) 
• 
Pre-medication 
• 
Sym004 iv infusion 
 
Cycle 1, Day 15 
• 
Interval history and brief physical exam 
• 
Vital signs, including blood pressure and weight (Calculate BMI) 
• 
Skin toxicity assessment 
• 
Toxicity assessment (continuous throughout the study) 
• 
Hematology including CBC/differential 
• 
CMP + Mg 
• 
Sym004 iv infusion 
 

Pro00063483:  Ph.2 Sym004 for Recurrent GBM 
Version:  07/5/2017 
 
PT-PhI-II v04.30.14 
Duke Cancer Institute 
Page 21 of 50 
CONFIDENTIAL 
 
Cycle 2, Day 1 +/- 4 days (and for even numbered cycles, Day 1) (Tests or procedures should be performed prior 
to beginning the cycle.) 
• 
Interval history and brief physical exam 
• 
Vital signs, including blood pressure and weight (Calculate BMI) 
• 
Hematology including CBC/differential 
• 
CMP + Mg 
• 
Skin toxicity assessment 
• 
Toxicity assessment (continuous throughout the study) 
• 
Sym004 iv infusion 
 
Cycle 2, Day 15 +/- 4 days (and for even numbered cycles, Day 15) 
• 
Interval history and brief physical exam 
• 
Vital signs, including blood pressure and weight (Calculate BMI) 
• 
Skin toxicity assessment 
• 
Toxicity assessment (continuous throughout the study) 
• 
Hematology including CBC/differential 
• 
CMP + Mg 
• 
Sym004 iv infusion 
 
Cycle 3, Day 1 +/- 4 days (and for odd numbered cycles, Day 1) (Tests or procedures should be performed prior to 
beginning the cycle.) 
• 
Interval history and full physical exam, including a full neurologic assessment and KPS 
• 
Vital signs, including blood pressure and weight (Calculate BMI) 
• 
Hematology including CBC/differential  
• 
CMP + Mg 
• 
MRI of the brain (MRIs should be obtained every 8 weeks (i.e. every other cycle), prior to the start of the 
next cycle.) 
• 
Quality of life measurements (should be performed prior to other study-related evaluations at study visits, if 
at all possible)  
• 
Skin toxicity assessment 
• 
Toxicity assessment (continuous throughout the study) 
• 
Sym004 iv infusion 
 
Cycle 3, Day 15 +/- 4 days (and for odd numbered cycles, Day 15) 
• 
Interval history and brief physical exam 
• 
Vital signs, including blood pressure and weight (Calculate BMI) 
• 
Toxicity assessment (continuous throughout the study) 
• 
Hematology including CBC/differential 
• 
CMP + Mg 
• 
Skin toxicity assessment 
• 
Sym004 iv infusion 
10.4 Re-treatment Criteria (day 1 and day 15) 
Subjects must meet the following re-treatment criteria prior to infusion with Sym004, in order to receive the 
next scheduled infusion.  Dose modifications are allowed as described in Section 7.1.1. 
• 
ANC ≥ 1,000 cells/µl 
• 
Platelets ≥ 50,000 cells/µl 
• 
AST, bilirubin, creatinine ≤ 2.0 x upper limit of normal 
• 
Resolution of any grade 3 or greater toxicity felt to be possibly, probably or definitely attributable to the 
study regimen to grade 2 or lower based on the investigator’s decision. 
 

Pro00063483:  Ph.2 Sym004 for Recurrent GBM 
Version:  07/5/2017 
 
PT-PhI-II v04.30.14 
Duke Cancer Institute 
Page 22 of 50 
CONFIDENTIAL 
 
If treatment with Sym004 is delayed for longer than 2 weeks due to toxicities (i.e. grade 3-4 non-hematologic 
toxicities secondary to Sym004, such as skin toxicities, electrolyte disturbances, and gastrointestinal symptoms, 
or grade 4 neutropenia or thrombocytopenia), the MRI assessment that would normally occur prior to beginning 
a new cycle or at the end of treatment will still be obtained no later than 8 + 2 weeks after the previous MRI 
assessment.  Once the toxicities have resolved to meet re-treatment criteria, the subject will resume Sym004.  
The day Sym004 is resumed will be considered Day 1 of the next cycle expected for the subject, which means 
that we will omit day 15 infusion for the previous cycle. 
10.5 End of Treatment 
The End of Treatment visit, i.e. the date of a subject’s last treatment visit, should include: 
• 
Interval history and full physical exam, including a full neurologic assessment and KPS 
• 
Vital signs, including blood pressure and weight 
• 
Hematology including CBC/differential  
• 
CMP + Mg 
• 
MRI of the brain 
• 
Quality of life measurements (should be performed prior to other study-related evaluations at study visits, if 
at all possible) 
• 
Skin toxicity assessment 
• 
Toxicity assessment  
 
If a subject goes off study and does not return to clinic as part of a regular study visit, not all tests listed above 
may be obtained as part of end of treatment, e.g. magnesium.   If this occurs, only the assessments that are 
reasonably obtainable will be collected as part of end of treatment. 
10.6 Follow-up Period 
Patients will be followed for safety a minimum of 30 days after last dose of study drug, and also followed for any 
new and/or unresolved serious adverse events considered related to study therapy.   Once “off study,” subjects 
will be followed for progression (for patients who came off study prior to disease progression) and survival status 
(all patients)at least 1 year, if possible. Subjects not returning to Duke will be contacted via phone or information 
will be obtained through their local physician every 3 months to determine time of progression or survival.  
10.7 End of Study 
The study will be considered complete once enrollment has been met, follow-up procedures on all subjects have 
been conducted, and data analysis is concluded.  The study may also be terminated early for any reason by the 
PI-sponsor.  In order to close the study with the Duke IRB, all desired data extraction and analysis must be 
complete.  Therefore, if any articles for publication are derived from the current study, they must be submitted 
and accepted with no further need for additional data extraction or analysis prior to termination with the IRB. 
 
Subjects that are lost to follow-up will be documented in the patient record and in the 21 CFR Part 11 compliant 
database.  In the eCRF , the subject will be marked as “Patient Status Unknown,” along with a corresponding 
explanation, if any.  This status may also be documented on an “Off Study Form” in the eCRF. 
10.8 Early Withdrawal of Subject(s) 
10.8.1 Criteria for Early Withdrawal 
Subjects may voluntarily withdraw from the study at any time.  The PI may also withdraw a subject from 
the study at any time based on his/her discretion.  Reasons for PI-initiated withdrawal may include, but 
are not limited to, the following: 
• 
Progressive disease as documented by MRI or physical examination at any time after the completion 
of therapy 
• 
Pregnancy 

Pro00063483:  Ph.2 Sym004 for Recurrent GBM 
Version:  07/5/2017 
 
PT-PhI-II v04.30.14 
Duke Cancer Institute 
Page 23 of 50 
CONFIDENTIAL 
 
• 
Upon request of the subject 
• 
If, in the investigator’s medical judgment, further participation would be injurious to the subject’s 
health or well-being 
• 
Development of intolerable symptoms 
• 
Protocol deviation 
• 
Administrative reasons, such as a major violation of the clinical trial protocol 
• 
Non-compliance of the subject 
10.8.2 Follow-up Requirements for Early Withdrawal 
If an enrolled subject withdraws from the study prematurely, they will be asked to complete the 
tests/procedures that would have been conducted at their next scheduled visit, if physically possible.  
Patients will be followed for a minimum of 30 days after last dose of study drug, and also followed for any 
new and/or unresolved serious adverse events considered related to study therapy. 
10.8.3 Replacement of Early Withdrawal(s) 
Subjects that withdraw early from the study will only be replaced if they did not begin study-related 
treatment with Sym004.   
10.9 Study Assessments 
10.9.1 Medical History 
Standard initial and interval medical histories will be obtained and documented per institutional 
guidelines, and should include an assessment of toxicities/side effects experienced by the subject. 
10.9.2 Physical Exam and Neurological Assessment 
Standard full physical exam and neurological assessment will be conducted and documented per 
institutional and PRTBTC guidelines.  Per institutional guidelines, full exams must take place at MRI visits 
(e.g. Cycle 3, Day 1).  Visits where an infusion is received and no is MRI scheduled only include a brief 
physical, as well as vital signs and weight.   
10.9.3 Radiographic Review 
The RANO criteria will be used to determine progression and pseudo-progression, as defined by Wen et 
al., 2010 (see Appendix B).12 
10.9.4 Skin Toxicity Assessments 
Skin toxicity will be evaluated at each clinic visit, beginning with Cycle 1 Day 15, and patients will be 
instructed to call if the rash is painful or interfering with daily functioning.  If a rash is identified, it should 
be treated according to Duke Medicine’s “Guidelines for Management of Cutaneous Toxicity for Patients 
Receiving Epidermal Growth Factor Receptors” (see Appendix A), in conjunction with Symphogen’s “Skin 
Management Booklet” for Sym004. 
10.9.5 Correlative Assessments 
We will determine EGFRvIII status as part of an exploratory objective looking at the efficacy of Sym004 in 
EGFRvIII positive patients.  Archival tissue will be used for this purpose; however, if a subject has more 
than one source of archival tissue, each source may be requested to determine if EGFRvIII status has 
changed over time.  EGFR expression will be determined by FISH and and EGFRvIII expression will be 
determined using IHC by the Duke Department of Pathology if not previously obtained. 
  

Pro00063483:  Ph.2 Sym004 for Recurrent GBM 
Version:  07/5/2017 
 
PT-PhI-II v04.30.14 
Duke Cancer Institute 
Page 24 of 50 
CONFIDENTIAL 
 
10.9.6 Laboratory Evaluations 
The timing of laboratory assessments that will be obtained during the course of the study is given in 
Section 10.  A list of each evaluation and what they include, when done at a Duke facility, is below. 
• 
CBC with differential (hematocrit, hemoglobin, platelet count, white blood cell count, mean 
corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, 
NRBC %, NRBC CT, RDW-CV, absolute lymphocyte count, percent lymphocytes, percent monocytes, 
percent neutrophils, percent eosinophils, percent basophils, absolute monocyte count, absolute 
neutrophil count, absolute eosinophil count, absolute basophil count, red blood cell count) 
• 
CMP + Mg (albumin, alanine aminotransferase, alkaline phosphatase , aspartate aminotransferase, 
total bilirubin , total protein, calcium, potassium, sodium, carbon dioxide creatinine, urea nitrogen, 
glucose, chloride + magnesium) 
• 
Beta-HCG, if applicable, within 48 hours prior to start of study treatment 
10.9.7 Quality of Life Assessments 
Quality of Life will be assessed using standardized and validated questionnaires as described in Section 
7.1.8.  References for these standardized tests are provided in Section 15. 
11 SAFETY MONITORING AND REPORTING 
The PI is responsible for the identification and documentation of adverse events and serious adverse events, as 
defined below.  At each study visit, the PI or designee must assess, through non-suggestive inquiries of the subject or 
evaluation of study assessments, whether an AE or SAE has occurred.  This study will utilize the DCI Safety Desk for all 
SAE reporting to the Duke IRB and to the study supporter, Symphogen.  The study team will follow DCI Safety Desk 
Standard Operation Procedures (SOPs). 
11.1 Adverse Events 
An adverse event (AE) is any untoward medical occurrence in a subject receiving study drug and which does not 
necessarily have a causal relationship with this treatment.  For this protocol, the definition of AE also includes 
worsening of any pre-existing medical condition.  An AE can therefore be any unfavorable and unintended or 
worsening sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the 
use of Sym004, whether or not related to use of the Sym004.  Abnormal laboratory findings without clinical 
significance (based on the PI’s judgment) should not be recorded as AEs.  But laboratory value changes that 
require therapy or adjustment in prior therapy are considered adverse events. 
 
From the time the subject signs the informed consent form through the End of Study visit (as defined in Section 
10.5), all AEs must be recorded in the subject medical record and adverse events case report form. 
 
AEs will be assessed according to the CTCAE version 4.0.  If CTCAE grading does not exist for an AE, the severity 
of the AE will be graded as mild (1), moderate (2), severe (3), life-threatening (4), or fatal (5). 
 
Attribution of AEs will be indicated as follows: 
• 
Definite:  The AE is clearly related to the study drug 
• 
Probably:  The AE is likely related to the study drug 
• 
Possible:  The AE may be related to the study drug 
• 
Unlikely:  The AE is doubtfully related to the study drug 
• 
Unrelated:  The AE is clearly NOT related to the study drug 
11.1.1 Overview of Clinical Findings and side effects 
According to the Investigator’s Brochure (v. 8.0, 13-Mar-2017), skin toxicities were the most frequently 
reported AEs.  To date (20 Jan 2017), approximately 380 subjects with solid tumors, including subjects 
with recurrent/metastatic SCCHN, mCRC, ESCC and NSCLC, have been treated with Sym004 in weekly 

Pro00063483:  Ph.2 Sym004 for Recurrent GBM 
Version:  07/5/2017 
 
PT-PhI-II v04.30.14 
Duke Cancer Institute 
Page 25 of 50 
CONFIDENTIAL 
 
doses of up to 12 mg/kg and in doses every other week of up to 18 mg/kg in ongoing Symphogen-
sponsored studies.  Anti-EGFR related skin toxicities (including rash, pruritus, skin fissures, dry skin, 
erythema, and paronychia) have been observed in more than 90% of subjects in the completed and 
ongoing clinical trials.  In subjects who had previously received anti-EGFR mAb therapy, Grade 3 skin 
toxicities were frequently reported; 50-69% of subjects at a dose of 9 or 12 mg/kg weekly (Sym004-01 
Parts B and C and Sym004-02) and 33.3% and 41.2% of subjects at dose levels of 12 mg/kg and 18 mg/kg, 
respectively, every other week (Sym004-01 Parts D and E). 
 
Other adverse events (AEs) associated with anti-EGFR mAbs, such as electrolyte disturbances (in particular 
hypomagnesemia), mucositis, and diarrhea were also frequently observed in the completed and ongoing 
trials.   In clinical trials for which AE data are available (Sym004-01-Parts A, B, C, D, E, Sym004-02, and EMR 
200637-001-Part A), hypomagnesemia was reported in 54-77% of subjects, and 0-38% of subjects 
experienced Grade 3 or 4 hypomagnesemia. In the Sym004-01 and Sym004-02 clinical trials, events of 
hypomagnesemia also represented the majority of serious adverse events (SAEs) that were considered to 
be related to Sym004 therapy.  Serious clinical complications of hypomagnesemia have not been 
observed.  Mucositis was observed in up to 40% of subjects, but the number of subjects experiencing 
Grade 3 mucositis was low (1 subject).  Diarrhea has been reported in up to 59% of subjects; and ≤ 10% of 
subjects experienced Grade 3 diarrhea.  Infusion related reactions have also been observed. 
 
The expected adverse drug reactions are related to the biological mode of action of Sym004 through 
internalization and degradation of the EGFR receptor and to infusion of a foreign protein agent (infusion-
related reactions).   
 
At a minimum, the following relevant categories of adverse drug reactions are expected to occur in 
relation to administration of Sym004: 
• 
Electrolyte imbalances, including hypomagnesaemia, hypocalcemia and hypokalemia (early and 
aggressive replacement therapy of magnesium is emphasized) 
• 
Dermatological toxicities, acneiform rash, skin drying and fissuring, and secondary infections. 
Prophylactic treatment is allowed. 
• 
Infusion reactions of variable severity, requiring medical intervention and potential discontinuation 
• 
Other adverse drug reactions cannot be excluded. Therefore, the patients must be closely monitored 
and Sym004 should be administered in an environment where full resuscitation facilities are available. 
11.1.2 Reporting of AEs 
Symphogen Global Pharmacovigilance will be provided via secure email with AE listings as appropriate, in 
order for analysis to be performed for the Symphogen Development Safety Update Report (DSUR) (after 
Data Lock Point [DLP]  for the report on January 20th).  
11.2 Serious Adverse Events 
An AE is considered “serious,” if in the opinion of the investigator, it results in one of the following outcomes: 
• 
Fatal 
• 
Life-threatening 
• 
Constitutes a congenital anomaly or birth defect 
• 
A medically significant condition (defined as an event that compromises subject safety or may require 
medical or surgical intervention to prevent one of the three outcomes above). 
• 
Requires inpatient hospitalization or prolongation of existing hospitalization 
• 
Results in persistent or significant incapacity or substantial disruption to conduct normal life functions. 

Pro00063483:  Ph.2 Sym004 for Recurrent GBM 
Version:  07/5/2017 
 
PT-PhI-II v04.30.14 
Duke Cancer Institute 
Page 26 of 50 
CONFIDENTIAL 
 
11.2.1 Reporting of SAEs to Duke Cancer Institute Safety Desk 
Adverse events that are serious and unexpected are considered reportable.  Reportable events that occur  
during  the study, beginning at the time of first study drug treatment infusion)  to within 30 days following 
cessation of study drug treatment are reportable.   
 
The study team will complete the DCI SAE Report Form and the DCI Safety Review Form, which will both 
be submitted to the DCI Safety Desk (Fax #: 919-681-9357 or secure email to dcccsafe@dm.duke.edu) and 
to the PI, Dr. Annick Desjardins, MD, FRCPC (email: annick.desjardins@duke.edu) or her designee within 
24 hours of knowledge of the event. 
 
The initial report for each SAE  should include at minimum the following information: 
• 
protocol # and title 
• 
patient initials, study identification number, sex, age or date of birth 
• 
date the event occurred 
• 
description of the SAE 
• 
dose level and cycle number at the time the SAE occurred 
• 
description of the patient’s condition 
• 
indication whether the patient remains on study 
• 
causality or causal relationship 
 
The DCI Safety Desk will track individual SAE reports into their internal tracking database and complete 
the initial processing within 2 business days of receipt.  For unanticipated study-related event(s), these will 
be processed within 1 business day of receipt. 
 
De-identified source documentation (i.e. admission notes, discharge notes, applicable laboratory results, 
radiology/diagnostic testing results, etc.) should be sent with the SAE Report Form, if available at the time 
of the report.  Any follow-up information including severity, action taken, concomitant medications, and 
outcome should be communicated to the DCI Safety Desk, as soon as possible using the same forms 
mentioned above.  The study team should keep a copy of the initial SAE forms submitted to the DCI safety 
desk and any SAE follow up forms for reference. 
 
The DCI Safety Desk will use the information provided in the DCI SAE Report Form and the DCI Safety 
Review Form to complete a FDA Form 3500A, and will submit it to the Duke University IRB, if it meets 
Duke IRB reporting requirements (see below).   
 
Only adverse events that the Duke Sponsor-Investigator determines to be serious, unanticipated, and 
related or possibly/probably (i.e. more likely than not) related to the research must be reported to the 
Duke IRB.  Those adverse events will be submitted in the electronic IRB (eIRB) system, according the 
following guidelines: 
• 
Report within 24 hours of learning about any subject’s death that was unanticipated and more likely 
related to the research than unrelated; 
• 
Report within 5 business days of learning about any serious, unanticipated, and related or 
possibly/probably related adverse event; 
• 
Report within 10 business day of learning about any other unanticipated problem or event that was 
more likely related to the research than unrelated. 
• 
The Sponsor-Investigator must report to the FDA, in an IND safety report, any suspected adverse 
reaction that is both serious and unexpected. Before submitting this report, the sponsor needs to 
ensure that the event meets all three of the definitions contained in the requirement:  
o 
Suspected adverse reaction (i.e. there is a reasonable possibility that the drug caused the 
adverse event) 
o 
Serious  
o 
Unexpected  

Pro00063483:  Ph.2 Sym004 for Recurrent GBM 
Version:  07/5/2017 
 
PT-PhI-II v04.30.14 
Duke Cancer Institute 
Page 27 of 50 
CONFIDENTIAL 
 
 
If the adverse event does not meet all three of the definitions, it should not be submitted as an expedited 
IND safety report. 
11.2.2 Reporting to the FDA 
All SAE’s that are possibly/probably related (i.e. there is evidence to suggest a causal relationship) and 
unexpected must be reported to the FDA as IND Safety Reports. The Sponsor-Investigator is required to 
report to the FDA all IND Safety reports in writing within 15 days (7 days for unexpected fatal or life-
threatening suspected (possibly/probably related) adverse reactions) per 21CFR312.32.   
 
The FDA Form 3500A can be found on the FDA website, www.fda.gov.  All other adverse events will be 
reported to the FDA in the Annual Report. 
 
 This will be done by the study team in cooperation with the DCI Safety Desk. 
11.2.3 Safety Reporting to Symphogen Global Pharmacovigilance 
The Investigator shall have full responsibility for the scientific, medical and legal/regulatory conduct of the 
trial, as well as for study documentation and safety reporting responsibilities.  The Investigator shall 
promptly report to Symphogen all safety-related information obtained from the study as follows: 
 
For all expedited SAE reports (Initial or Follow-up) and any death (regardless of causality) that occurs 
while a subject is on study, i.e. within 30 days of the last study drug administration, regardless of any 
opinion as to the relationship of the SAE to the study drug, Symphogen Global Pharmacovigilance must be 
notified by telephone, fax, or secure email within 2 business days of the PI or designee first becoming 
aware of the event and the study team notifying the DCI safety desk of the event.  Any urgent safety issue 
or communication with FDA concerning such issue should be made known to Symphogen within 24 hours 
of the PI or designee first becoming aware of the event and the study team notifying the DCI safety desk 
of the event. 
 
All SAEs require that a Serious Adverse Event Report Form (either DCI Safety Desk SAE Report and Safety 
Review Forms or a MedWatch Form 3500A) be completed and forwarded to Symphogen either via fax 
transmission or secure email.  The SAE Form must include a description narrative, inclusive of the 
investigator’s causality assessment. 
 
All non-expedited serious adverse events (SAEs) will be forwarded to Symphogen Pharmacovigilance 
within 7 calendar days of first knowledge of the event by secure email or fax transmission.  
 
Any request by Symphogen for safety data that would need to be incorporated into the DSUR generated 
by Symphogen for its reporting purposes will be provided in a timely fashion, in order for Symphogen to 
meet its reporting timelines. 
 
Contact Information for Symphogen Global Pharmacovigilance 
Email Forms: GlobalPV@symphogen.com 
Drug Safety Telephone line:  908-378-9630 
Safety Fax line:  908-378-9654  
11.2.4 Exposure in Utero 
While reports of pregnancy are not considered SAEs, these events will be tracked for follow-up purposes 
and assessing outcome in the infant.  If any trial subject or the female partner of a male trial subject 
becomes pregnant during the time of receiving study drug, or is found to be pregnant within 90 days of 

Pro00063483:  Ph.2 Sym004 for Recurrent GBM 
Version:  07/5/2017 
 
PT-PhI-II v04.30.14 
Duke Cancer Institute 
Page 28 of 50 
CONFIDENTIAL 
 
the last dose of study drug, Symphogen will be notified by the DCI Safety Desk within 1 business day of the 
DCI Safety Desk learning of the event via fax or email and a Pregnancy Reporting Form will need to be 
completed. The pregnancy will be followed to term and all pregnancy information will be tracked within 
the Symphogen safety database. 
11.3 Emergency Unblinding of Investigational Treatment 
Not applicable. 
11.4 Other Reportable Information 
Not applicable. 
11.5 Special Warnings and Precautions 
Not applicable. 
11.6 Safety Oversight Committee (SOC) 
The Duke Cancer Institute SOC is responsible for annual data and safety monitoring of DUHS sponsor-investigator 
phase 1 and 2, therapeutic interventional studies that do not have an independent Data Safety Monitoring Board 
(DSMB).  The primary focus of the SOC is review of safety data, toxicities and new information that may affect 
subject safety or efficacy.  Annual safety reviews include but may not be limited to review of safety data, 
enrollment status, stopping rules if applicable, accrual, toxicities, reference literature, and interim analyses as 
provided by the sponsor-investigator.  The SOC in concert with the DCI Monitoring Team (see Section 12.1 for 
Monitoring Team description) oversees the conduct of DUHS cancer-related, sponsor-investigator greater-than-
minimal-risk intervention studies that do not have an external monitoring plan, ensuring subject safety and that 
the protocol is conducted, recorded and reported in accordance with the protocol, standing operating 
procedures (SOPs), Good Clinical Practice (GCP), and applicable regulatory requirements. 
11.7 External Data and Safety Monitoring Board (DSMB) 
Not applicable. 
12 QUALITY CONTROL AND QUALITY ASSURANCE 
12.1 Monitoring 
The Duke Cancer Institute (DCI) Monitoring Team will conduct monitoring visits to ensure subject safety and to 
ensure that the protocol is conducted, recorded, and reported in accordance with the protocol, standard 
operating procedures, good clinical practice, and applicable regulatory requirements.  As specified in the DCI 
Data and Safety Monitoring Plan, the DCI Monitoring Team will conduct routine monitoring after the third 
subject is enrolled, followed by annual monitoring of 1 – 3 subjects until the study is closed to enrollment and 
subjects are no longer receiving study interventions that are more than minimal risk.   Monitoring additional to 
the standard practice of the DCI may occur as per contractual agreement with Symphogen.  
 
Additional monitoring may be prompted by findings from monitoring visits, unexpected frequency of serious 
and/or unexpected toxicities, or other concerns and may be initiated upon request of DUHS and DCI leadership, 
the DCI Cancer Protocol Committee, the Safety Oversight Committee (SOC), the sponsor, the Principal 
Investigator, or the IRB.  All study documents must be made available upon request to the DCI Monitoring Team 
and other authorized regulatory authorities, including but not limited to the National Institute of Health, 
National Cancer Institute, and the FDA.  Every reasonable effort will be made to maintain confidentiality during 
study monitoring. 
12.2 Audits 
The Duke School of Medicine Office of Audit, Risk, and Compliance (OARC) office may conduct confidential audits 
to evaluate compliance with the protocol and the principles of GCP.  The PI agrees to allow the OARC  and 

Pro00063483:  Ph.2 Sym004 for Recurrent GBM 
Version:  07/5/2017 
 
PT-PhI-II v04.30.14 
Duke Cancer Institute 
Page 29 of 50 
CONFIDENTIAL 
 
auditor(s) direct access to all relevant documents and to allocate his/her time and the time of the study team to 
the auditor(s) in order to discuss findings and any relevant issues. 
 
OARC  audits are designed to protect the rights and well-being of human research subjects.  Audits may be 
routine or directed (for cause). Routine audits are selected based upon risk metrics generally geared towards 
high subject enrollment, studies with limited oversight or monitoring, Investigator initiated Investigational Drugs 
or Devices, federally-funded studies, high degree of risk (based upon adverse events, type of study, or vulnerable 
populations), Phase I studies, or studies that involve Medicare populations. Directed audits occur at the directive 
of the IRB or an authorized Institutional Official. 
 
OARC  audits examine research studies/clinical trials methodology, processes and systems to assess whether the 
research is conducted according to the protocol approved by the DUHS IRB. The primary purpose of the 
audit/review is to verify that the standards for safety of human subjects in clinical trials and the quality of data 
produced by the clinical trial research are met. The audit/review will serve as a quality assurance measure, 
internal to the institution. Additional goals of such audits are to detect both random and systemic errors 
occurring during the conduct of clinical research and to emphasize “best practices” in the research/clinical trials 
environment. 
12.3 Data Management and Processing 
12.3.1 Case Report Forms (CRFs) 
The electronic CRF (eCRF) will be the primary data collection document for the study.  The CRFs will be 
updated in a timely manner following acquisition of new source data.  Only approved study staff (the PI, 
the research coordinators, the research nurses, the data management team, and the clinical trials 
manager) are permitted to make entries, changes, or corrections in the CRF. 
 
An audit trail will be maintained automatically by the electronic CRF management system, which will be a 
21 CFR Part 11 compliant database.  All users of this system will complete user training, as required or 
appropriate per DCI requirements and other regulations. 
12.3.2 Data Management Procedures and Data Verification 
Designated personnel using the electronic CRF will have access based on their specific roles in the 
protocol. 
 
Completeness of entered data will be checked automatically by the eCRF system, and users will be alerted 
to the presence of data inconsistencies.  Additionally, the data management team and the statistical team 
will cross-reference the data to verify accuracy.  Missing or implausible data will be highlighted for the PI 
requiring appropriate responses (i.e. confirmation of data, correction of data, completion or confirmation 
that data is not available, etc.). 
 
The database will be reviewed and discussed prior to database closure, and will be closed only after 
resolution of all remaining queries.  An audit trail will be kept of all subsequent changes to the data. 
12.3.3 Study Closure 
Following completion of the studies, the PI will be responsible for ensuring the following activities: 
• 
Data clarification and/or resolution 
• 
Accounting, reconciliation, and destruction/return of used and unused study drugs 
• 
Review of site study records for completeness 
• 
Shipment of all remaining laboratory samples to the designated laboratories 

Pro00063483:  Ph.2 Sym004 for Recurrent GBM 
Version:  07/5/2017 
 
PT-PhI-II v04.30.14 
Duke Cancer Institute 
Page 30 of 50 
CONFIDENTIAL 
 
13 STATISTICAL METHODS AND DATA ANALYSIS 
All statistical analysis will be performed under the direction of the statistician designated in key personnel.  Any data 
analysis carried out independently by the PI must be approved by the statistician before publication or presentation. 
 
With Amendment 31, the study has been modified to allow the assessment of activity of two different doses of 
Sym004:  18 mg/kg and 24 mg/kg.  With the increase to 24 mg/kg dose, we intend to treat 65 additional subjects at 
that dose level (36 in Cohort 1, and 29 in Cohort 2).  The maximum accrual goal for this study is the number of 
subjects accrued before Amendment 31 plus 65 more. 
13.1 Analysis Sets 
Safety and efficacy analyses will include all patients who received any Sym004 treatment. 
13.2 Patient Demographics and Other Baseline Characteristics 
Socio-demographic and clinical characteristics of patients enrolled onto this study will be summarized by study 
cohort and dose level.  For categorical variables, frequencies and percentages will be provided.  Means with 
standard deviations or medians/percentiles will summarize non-categorical variables. 
13.3 Treatments 
Within each cohort and dose level, a frequency distribution will be generated for the number of doses of Sym004 
administered.   In addition, the frequency of dose reduction will also be tabulated. 
13.4 Primary Objective 
The primary objective of the study is to assess the activity of Sym004 within two cohorts of patients with 
recurrent glioblastoma based upon PFS6:  patients who are non-bevacizumab failures (Cohort 1) and patients 
who have previously failed bevacizumab (Cohort 2).  This assessment will be done at both dose levels. 
13.4.1 Variable 
The primary endpoint is PFS6, which is defined as the proportion of patients who remain alive and 
progression-free 6 months after initiation of Sym004 treatment.  The use of PFS6 as an endpoint in phase 
II clinical trials is recommended by Ballman (2007) and Lamborn (2008) given the strong association 
between progression-free survival status and overall.13,14 
13.4.2 Statistical Hypothesis, Model, and Method of Analysis 
Based upon the Kaplan-Meier estimator, the proportion of patients who are alive and progression-free 6 
months after initiation of Sym004 treatment will be estimated.  Details about the hypothesis test that will 
be conducted is provided in Section 13.8. 
 
The primary analyses will focus on the dose group to which the patient was originally assigned.  No more 
than 2 of the patients treated initially at the 18 mg/kg dose will have their dose escalated to 24 mg/kg.  
Efficacy analyses will be generated with and without these patients to assess the impact of these patients 
with dose escalation on inferences. 
13.4.3 Handling of missing values, censoring, and discontinuations 
The sample size justification provided in Section 13.8 assumes that all patients will be followed for their 
clinical status for at least 6 months or until death.  Historical data within the Preston Robert Tisch Brain 
Tumor Center suggests that such an assumption is fully achievable.  If patients are lost to follow-up prior 
to their 6-month outcome, estimates of PFS6 will be appropriately adjusted for such censoring in the 
estimation of the outcome from the Kaplan-Meier estimator. 

Pro00063483:  Ph.2 Sym004 for Recurrent GBM 
Version:  07/5/2017 
 
PT-PhI-II v04.30.14 
Duke Cancer Institute 
Page 31 of 50 
CONFIDENTIAL 
 
13.5 Secondary Objectives 
Secondary objectives are to determine the safety of Sym004 in recurrent GBM patients and to determine 
response rate (RR) and overall survival (OS) in recurrent GBM patients.  These analyses will be generated for both 
dose levels. 
13.5.1 Key Secondary Objective: Safety 
Within each cohort and dose level, the proportion of patients who experience grade 3, 4, or 5 adverse 
events that are possibly, probably, and definitely related to protocol treatment will be estimated. 
 
In addition, for each type of toxicity, the maximum grade experienced by each patient will be summarized 
with frequency distributions.  Two adverse experience tabulations will be generated, one that includes all 
toxicities regardless of attribution, and one that includes only toxicities that are possible, probably, and 
definitely related to Sym004 treatment. 
 
Patients who have their dose escalated from 18 mg/kg to 24 mg/kg will be included in toxicity summaries 
for 18 mg/kg and 24 mg/kg.  The toxicity experienced prior to dose escalation will be summarized with the 
other patients treated at the 18 mg/kg dose level; whereas, the toxicity experienced after dose escalation 
will be included in the summary of adverse events associated with 24 mg/kg. 
13.5.2 Other Secondary Objectives:  Response Rate and Survival 
Within each cohort and dose level, radiographic response rate will be estimated as the proportion of 
treated patients with a complete or partial response.  An exact binomial confidence interval will be 
generated. 
 
Kaplan-Meier curves will be generated to describe the PFS and OS experience of patients treated with 
Sym004 within each cohort and dose level.  Progression-free survival (PFS) is defined as the time interval 
between initiation of protocol treatment and either disease progression or death.  If the patient is alive 
and progression-free, PFS will be censored at the date last known alive.  Overall survival (OS) is defined as 
the time interval between initiation of protocol treatment and death, or date of last follow-up if alive.  
Estimates with confidence intervals will be generated for median PFS/OS, as well as 2 month intervals for 
PFS for the first year (2, 4, 6, etc..) and 6 month intervals for OS for the first 2 years (6,12, 18, 24) from the 
time the subject goes on  study. 
 
The analyses of response rate, OS, and PFS will focus on the dose group to which the patient was originally 
assigned.  The impact that the few patients treated initially at the 18 mg/kg dose and subsequently with 
24 mg/kg will be assessed by generating analyses with and without these patients. 
13.6 Exploratory Objectives 
There are two exploratory objectives for this study:  (1) Assess the impact of EGFRvIII expression on OS and PFS, 
and (2) Describe patient-reported quality of life outcomes (PROs).   
 
Within each cohort, dose level, and EGFRvIII expression group, Kaplan-Meier curves will be used to describe 
OS/PFS and to estimate median OS/PFS.  For each cohort, Cox proportional hazards model will be used to 
examine the joint effect of dose and EGFRvIII expression on PFS/OS. 
 
Descriptive statistics (e.g. means and standard deviations) will be used to summarize each quality of life subscale 
at each follow-up assessment.  These statistics will be generated for each cohort and dose level. 

Pro00063483:  Ph.2 Sym004 for Recurrent GBM 
Version:  07/5/2017 
 
PT-PhI-II v04.30.14 
Duke Cancer Institute 
Page 32 of 50 
CONFIDENTIAL 
 
13.7 Interim Analysis 
13.7.1 Interim Efficacy Analysis for 18 mg/kg Sym004 
Interim analyses for efficacy will not be conducted given the expected rapidity of patient accrual relative 
to the length of time required to observe the study’s primary outcome.  If a two-stage design were 
conducted with PFS6 as an endpoint, accrual would be suspended for up to 6 months to observe outcome 
for all patients within the first stage.  Depending upon the cohort, accrual to both stages of the study 
could have been completed during that period of accrual suspension. 
13.7.2 Interim Efficacy Analysis for 24 mg/kg Sym004 
With Amendment 31, the design of the study will be modified.  Within each cohort, a two-stage study 
design is used to assess outcome.  The statistical properties of this design are provided in section 13.8.2.  
However, the stopping rules for each cohort are summarized below.15  After stage 1 enrollment is 
completed, accrual will be temporarily suspended while data from the first stage matures unless at that 
point 1 or more patients have survived 6-months progression-free.    
 
Patients who have their dose escalated from 18 mg/kg to 24 mg/kg will not be considered in these interim 
efficacy analyses for 24 mg/kg Sym004. 
 
 

Pro00063483:  Ph.2 Sym004 for Recurrent GBM 
Version:  07/5/2017 
 
PT-PhI-II v04.30.14 
Duke Cancer Institute 
Page 33 of 50 
CONFIDENTIAL 
 
Monitoring Rules 
 
Cohort 1 
Cohort 2 
Statistical Hypothesis 
PFS6 ≤ 20% vs PFS6 ≥ 40% 
PFS6 ≤ 3% vs PFS6 ≥ 20% 
Stage 1 
Accrue 19 patients 
Accrue 12 patients 
Criteria for Accrual to Stage 2 
>3 patients who live 6+ months 
progression-free 
>0 patients who live 6+ months 
progression-free 
Stage 2 
Accrue 17 more patients 
Accrue 17 more patients 
 
13.7.3 Skin Toxicity Monitoring among Patients Treated with 18 mg/kg Sym004  
Interim analyses that focus on the physiologic consequences of Sym004 treatment will be conducted after 
19 total patients across both cohorts have been treated with Sym004.  The goal of the interim analysis is 
to determine whether the dose of Sym004 needs to be increased or decreased.  The basis of this decision 
will partly be based upon the prevalence of ≥ Grade 3 skin toxicity after the administration of 2 doses.  
However, other factors may contribute to this decision-making.  Accrual will be not be suspended while 
this assessment of skin toxicity is occurring.  The decision-making could result in 3 outcomes:  increase the 
dose, decrease the dose, or continue accruing at the current dose.  If a decision is made to modify the 
dose, the protocol will be appropriately amended. 
 
If the prevalence of skin toxicity is truly 30% (Symphogen unpublished data), then the dose of Sym004 is 
considered acceptable.  However, if the true prevalence of skin toxicity is much less or much greater than 
30%, then the dose of Sym004 may need modification.   Observing skin toxicity in 2 or fewer patients or 9 
or more patients is an indication that the data concerning dosing needs to be carefully scrutinized along 
with other available data.  The probability of observing this extent of skin toxicity as a function of the true 
probability of skin toxicity is tabulated below. 
 
True Probability of 
Skin Toxicity 
Probability of observing either 2 or fewer 
patients with skin toxicity, or observing 9 
or more patients with skin toxicity 
0.05 
0.933 
0.1 
0.705 
0.3 
0.130 
0.5 
0.677 
0.55 
0.816 
0.6 
0.912 
0.65 
0.965 
 
13.7.4 Initial Toxicity Monitoring among Patients Treated with 24 mg/kg Sym004 
Given limited experience with 24 mg/kg Sym004, the first 3-6 patients will be slowly accrued and carefully 
monitored for unacceptable toxicity (see Section 7.1.2). 
 
The first patient, regardless of cohort, will be treated and observed for 1 cycle before the accrual of a 
second patient.  During this period of observation, the patient will receive at minimum 2 full doses of 
Sym004 and be followed until the end of Cycle 1.  If the patient experiences an unacceptable adverse 
event (refer to Section 7.1.2), the study will be suspended and the patient’s experience will be discussed 
with Symphogen to determine whether patient accrual should continue.  Otherwise, 2 additional patients 
will be treated. 
 

Pro00063483:  Ph.2 Sym004 for Recurrent GBM 
Version:  07/5/2017 
 
PT-PhI-II v04.30.14 
Duke Cancer Institute 
Page 34 of 50 
CONFIDENTIAL 
 
The second and third patient can be accrued at the same time.  However, further accrual after the 3rd 
patient is suspended until completion of 1 cycle of therapy.  After the first 3 patients have been observed, 
the number of patients with unacceptable toxicity will be determined. 
 
• 
If none of the first 3 patients has an unacceptable toxic event, accrual will continue without further 
slowed accrual.     
• 
If 2 of the first 3 patients has an unacceptable toxicity, the study will remain suspended.  Results will 
be discussed with Symphogen with the expectation that accrual will be terminated.  
• 
If 1 of the first 3 patients has an unacceptable toxicity, an additional 3 patients can be accrued after 
which accrual will be suspended until all patients have been observed for at least 1 cycle.  If none of 
the additional 3 patients experiences an unacceptable toxicity, then accrual will resume without the 
requirement of staggered entry.  If 1 of these 3 patients experiences an unacceptable toxicity, the 
study will remain suspended while a discussion occurs with Symphogen to determine if accrual is 
terminated. 
 
For initial monitoring of the 24 mg/kg dose of Sym004, an unacceptable adverse event is defined as any 
grade 3, 4, or 5 adverse event that is definitely, possibly, or potentially related to Sym004 treatment. 
 
Patients who have their dose escalated from 18 mg/kg to 24 mg/kg will be considered as part of this 
interim analyses of toxicity at the 24 mg/kg if they are among the first 3 (or 6) patients who receive 
Sym004 at the 24 mg/kg dose level. 
13.8 Sample Size Calculation 
13.8.1 Sample Size Requirements for 18 mg/kg Sym004 
The sample size requirements within each cohort of patients will be considered separately. 
 
Non-Bevacizumab Failures (Cohort 1):  In a recent phase 3 study among patients with recurrent 
glioblastoma, a PFS6 rate of 19% (approximate 95% confidence interval: 12% - 30%) was observed for 
patients treated with lomustine.16  If the true PFS6 associated with SYM004 is comparable to that seen 
with lomustine or approximately 20%, there is limited interest in further investigation of SYM004 in this 
patient population.  However, if the true PFS6 is 40% or greater, there is interest in further investigation of 
the experimental treatment within this patient population.  With 36 patients, there is 90% power to 
differentiate between a PFS6 rate of 20% and 40% assuming a test conducted at the 0.1 level of 
significance (1-tailed).  If 11 or more patients of the 36 patients live more than 6 months without disease 
progression, the treatment will be considered worthy of further investigation in this patient population.   
 
Bevacizumab Failure (Cohort 2):  A recent publication from the Preston Robert Tisch Brain Tumor Center 
reported a PFS6 rate of 2.3% (95% CI: 0.2, 10.4) among patients who received non-bevacizumab treatment 
after progression on bevacizumab treatment administered in the recurrent setting.17  If the true PFS6 
associated with SYM004 within this patient population is comparable to that observed in this publication 
or about 3%, there is limited interest in further investigation of the agent in this setting.  However, if the 
true PFS6 rate is 20% or greater, there is interest in further clinical investigation.  With 25 patients, there 
is 90% power to differentiate between a PFS6 rate of 3% and 20% assuming a test conducted at the 0.1 
level of significance.  If 3 or more patients of the 25 live more than 6 months without disease progression, 
the treatment is worthy of further investigation. 
13.8.2 Sample Size Requirements for 24 mg/kg Sym004 
Prior to Amendment 31, the original goal was to accrue 61 subjects to receive 18 mg/kg Sym004, with 36 
patients in Cohort 1 and 25 in Cohort 2.  After the approval of Amendment 31, no additional subjects will 
be enrolled at 18 mg/kg.    
 

Pro00063483:  Ph.2 Sym004 for Recurrent GBM 
Version:  07/5/2017 
 
PT-PhI-II v04.30.14 
Duke Cancer Institute 
Page 35 of 50 
CONFIDENTIAL 
 
After Amendment 31, the effect of 24 mg/kg Sym004 treatment on PFS6 will be assessed in two cohorts 
with a maximum of 36 patients in Cohort 1 and 29 in Cohort 2.  With Amendment 31, the design of the 
study will be modified.  Within each cohort, either a two-stage minimax or two-stage optimal design will 
be used to assess PFS6.15  The same benchmarks that were used with 18 mg/kg Sym004 are used here 
with the same targeted type I and II error rates (i.e. α = β = 0.1). 
 
Patients originally treated at the 18 mg/kg dose level who have their dose escalated to 24 mg/kg will not 
be considered in these analyses.   
 
Non-Bevacizumab Failures (Cohort 1):  A minimax two-stage design will test the hypothesis that the true 
PFS is 20% or less versus the alternative that the true PFS is 40% or greater. After testing the treatment on 
19 patients in the first stage, the trial will be terminated if 3 or fewer patients live 6 months or more 
progression-free.  Otherwise, additional patients will be accrued so a total of 36 patients will be treated.  If 
the total number of patients living 6 months or more progression-free is less than or equal to 10, then the 
treatment is rejected as not worthy of further investigation in this patient population.  The expected 
sample size of 28.26 and the probability of early termination is 0.455.  The type I and II error rates are 
0.086 and 0.098, respectively.18   
 
Bevacizumab Failure (Cohort 2): An optimal two-stage design will be used to test the hypothesis that the 
true PFS is 3% or less versus the alternative that the true PFS is 20% or greater. After testing the treatment 
on 12 patients in the first stage, the trial will be terminated if 0 patients live 6 months or more 
progression-free.  Otherwise, the trial will continue and a total of 29 patients will be studied.  If 2 or more 
patients live 6 months or more progression-free the treatment will be considered worthy of further 
investigation.  The  expected sample size of 21.64 and the probability of early termination is 0.561.  The 
type I error rate if 0.038 and the type II error rate is 0.10.18   
14 ADMINISTRATIVE AND ETHICAL CONSIDERATIONS 
14.1 Regulatory and Ethical Compliance 
This protocol was designed and will be conducted and reported in accordance with the International Conference 
on Harmonization (ICH) Harmonized Tripartite Guidelines for Good Clinical Practice, the Declaration of Helsinki, 
and applicable federal, state, and local regulations. 
14.2 DUHS Institutional Review Board and DCI Cancer Protocol Committee 
The protocol, informed consent form, advertising material, and additional protocol-related documents must be 
submitted to the DUHS Institutional Review Board (IRB) and DCI Cancer Protocol Committee (CPC) for review.  
The study may be initiated only after the Principal Investigator has received written and dated approval from the 
CPC and IRB. 
 
The Principal Investigator must submit and obtain approval from the IRB for all subsequent protocol 
amendments and changes to the informed consent form.  The CPC should be informed about any protocol 
amendments that potentially affect research design or data analysis (i.e. amendments affecting subject 
population, inclusion/exclusion criteria, agent administration, statistical analysis, etc.). 
 
The Principal Investigator must obtain protocol re-approval from the IRB within 1 year of the most recent IRB 
approval.  The Principal Investigator must also obtain protocol re-approval from the CPC within 1 year of the 
most recent IRB approval, for as long as the protocol remains open to subject enrollment. 
14.3 Informed Consent 
The informed consent form must be written in a manner that is understandable to the subject population.  Prior 
to its use, the informed consent form must be approved by the IRB. 
 

Pro00063483:  Ph.2 Sym004 for Recurrent GBM 
Version:  07/5/2017 
 
PT-PhI-II v04.30.14 
Duke Cancer Institute 
Page 36 of 50 
CONFIDENTIAL 
 
The Principal Investigator or authorized key personnel will discuss with the potential subject the purpose of the 
research, methods, potential risks and benefits, subject concerns, and other study-related matters.  This 
discussion will occur in a location that ensures subject privacy and in a manner that minimizes the possibility of 
coercion.  Appropriate accommodations will be made available for potential subjects who cannot read or 
understand English or are visually impaired.  Potential subjects will have the opportunity to contact the Principal 
investigator or authorized key personnel with questions, and will be given as much time as needed to make an 
informed decision about participation in the study. 
 
Before conducting any study-specific procedures, the Principal Investigator must obtain written informed 
consent from the subject or a legally acceptable representative.  The original informed consent form will be 
stored with the subject’s study records, and a copy of the informed consent form will be provided to the subject.  
The Principal Investigator is responsible for asking the subject whether the subject wishes to notify his/her 
primary care physician about participation in the study.  If the subject agrees to such notification, the Principal 
Investigator will inform the subject’s primary care physician about the subject’s participation in the clinical study. 
14.4 Study Documentation 
Study documentation includes, but is not limited to, source documents, case report forms (CRFs), monitoring 
logs, appointment schedules, study team correspondence with sponsors or regulatory bodies/committees, and 
regulatory documents that can be found in the DCI-mandated “Regulatory Binder,” which includes, but is not 
limited to, approved protocol versions, approved informed consent forms, FDA Form 1572s, and CAP and CLIA 
laboratory certifications. 
 
Source documents are original records that contain source data, which is all information in original records of 
clinical findings, observations, or other activities in a clinical trial necessary for the reconstruction and evaluation 
of the trial.  Source documents include but are not limited to hospital records, clinical and office charts, 
laboratory notes, memoranda, subjects’ diaries or evaluation checklists, pharmacy dispensing records, recorded 
data from automated instruments, copies or transcriptions certified after verification as being accurate copies, 
microfiches, photographic negatives, microfilm or magnetic media, x-rays, subject files, and records kept at the 
pharmacy, at the laboratories and at medico-technical departments involved in the clinical trial.  DUHS utilizes 
Epic Maestro Care as an electronic health record.  When possible, the original record should be retained as the 
source document.  However, a photocopy is acceptable provided that it is a clear, legible, and an exact 
duplication of the original document. 
14.5 Privacy, Confidentiality, and Data Storage 
The Principal Investigator will ensure that subject privacy and confidentiality of the subject’s data will be 
maintained.  Research Data Security Plans (RDSPs) will be approved by the appropriate institutional Site Based 
Research group. 
 
To protect privacy, every reasonable effort will be made to prevent undue access to subjects during the course of 
the study.  Prospective participants will be consented in an exam room where it is just the research staff, the 
patient and his family, if desired. For all future visits, interactions with research staff (study doctor and study 
coordinators) regarding research activities will take place in a private exam room in Duke Cancer Center Clinic 3-
1. All research related interactions with the participant will be conducted by qualified research staff who are 
directly involved in the conduct of the research study. 
 
To protect confidentiality, subject files in paper format will be stored in secure cabinets under lock and key 
accessible only by the research staff. Subjects will be identified only by a unique study number and subject 
initials.  Electronic records of subject data will be maintained using a dedicated 21 CFR Part 11compliant 
database, which is housed in an encrypted and password-protected on a secure network drive.  Access to 
electronic databases (without edit rights) will be limited to the PI, the study coordinator, and the statistical team.  
The only personnel with both access and edit rights to the electronic databases are the data management team, 

Pro00063483:  Ph.2 Sym004 for Recurrent GBM 
Version:  07/5/2017 
 
PT-PhI-II v04.30.14 
Duke Cancer Institute 
Page 37 of 50 
CONFIDENTIAL 
 
including the clinical trials manager.  The security and viability of the IT infrastructure will be managed by the DCI 
and/or Duke Medicine.    
 
Upon completion of the study, research records will be archived and handled per DUHS HRPP policy, i.e. all files 
and documents that relate to the protection of human research participants are retained for at least 6 years 
following study completion (see Section 14.8 below for other study document storage guidelines).     
 
Subject names or identifiers will not be used in reports, presentations at scientific meetings, or publications in 
scientific journals. 
14.6 Data and Safety Monitoring 
Data and Safety Monitoring will be performed in accordance with the DCI Data and Safety Monitoring Plan.  For a 
more detailed description of the DSMP for this protocol,  refer to the Safety Monitoring and Reporting section 
and the Quality Control and Quality Assurance section. 
14.7 Protocol Amendments 
All protocol amendments must be initiated by the Principal Investigator and approved by the IRB prior to 
implementation.  IRB approval is not required for protocol changes that occur to protect the safety of a subject 
from an immediate hazard.  However, the Principal Investigator must inform the IRB and all other applicable 
regulatory agencies of such action immediately. 
 
Though not yet required, the CPC should be informed about any protocol amendments that potentially affect 
research design or data analysis (i.e. amendments affecting subject population, inclusion/exclusion criteria, 
agent administration, etc.). 
14.8 Records Retention 
The Principal Investigator will maintain study-related records for the longer of a period of: 
• 
At least two years after the date on which a New Drug Application is approved by the FDA (if an IND is 
involved) 
• 
At least two years after formal withdrawal of the Duke IND associated with this protocol (if an IND is 
involved) 
• 
At least six years after study completion (Duke policy) 
 
 

Pro00063483:  Ph.2 Sym004 for Recurrent GBM 
Version:  07/5/2017 
 
PT-PhI-II v04.30.14 
Duke Cancer Institute 
Page 38 of 50 
CONFIDENTIAL 
 
15 REFERENCES 
 
1. 
Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant 
temozolomide for glioblastoma. N Engl J Med 352:987-96, 2005 
 
2. 
Reardon DA, Wen PY, Desjardins A, et al: Glioblastoma multiforme: an emerging paradigm of anti-
VEGF therapy. Expert Opin Biol Ther 8:541-53, 2008 
 
3. 
Cancer Genome Atlas Research N: Comprehensive genomic characterization defines human 
glioblastoma genes and core pathways. Nature 455:1061-8, 2008 
 
4. 
Jones-Bolin S, Zhao H, Hunter K, et al: The effects of the oral, pan-VEGF-R kinase inhibitor CEP-7055 
and chemotherapy in orthotopic models of glioblastoma and colon carcinoma in mice. Mol Cancer Ther 5:1744-53, 
2006 
 
5. 
Dresemann G: Temozolomide in malignant glioma. Onco Targets Ther 3:139-46, 2010 
 
6. 
Ohgaki H, Kleihues P: The definition of primary and secondary glioblastoma. Clin Cancer Res 19:764-
72, 2013 
 
7. 
Wong AJ, Bigner SH, Bigner DD, et al: Increased expression of the epidermal growth factor receptor 
gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci U S A 84:6899-903, 
1987 
 
8. 
Sugawa N, Ekstrand AJ, James CD, et al: Identical splicing of aberrant epidermal growth factor 
receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci U S A 87:8602-6, 
1990 
 
9. 
Weitzner MA, Meyers CA, Gelke CK, et al: The Functional Assessment of Cancer Therapy (FACT) 
scale. Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary 
brain tumors. Cancer 75:1151-61, 1995 
 
10. 
Van Belle S, Paridaens R, Evers G, et al: Comparison of proposed diagnostic criteria with FACT-F and 
VAS for cancer-related fatigue: proposal for use as a screening tool. Support Care Cancer 13:246-54, 2005 
 
11. 
Beck AT, Steer RA, Ball R, et al: Comparison of Beck Depression Inventories -IA and -II in psychiatric 
outpatients. J Pers Assess 67:588-97, 1996 
 
12. 
Wen PY, Macdonald DR, Reardon DA, et al: Updated response assessment criteria for high-grade 
gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963-72, 2010 
 
13. 
Ballman KV, Buckner JC, Brown PD, et al: The relationship between six-month progression-free 
survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro 
Oncol 9:29-38, 2007 
 
14. 
Lamborn KR, Yung WKA, Chang SM, et al: Progression-free survival: An important end point in 
evaluating therapy for recurrent high-grade gliomas. Neuro Oncol 10:162-170, 2008 
 
15. 
Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989 
 
16. 
Wick W, Puduvalli VK, Chamberlain MC, et al: Phase III study of enzastaurin compared with 
lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 28:1168-74, 2010 
 
17. 
Reardon DA, Herndon JE, Peters KB, et al: Bevacizumab continuation beyond initial bevacizumab 
progression among recurrent glioblastoma patients. British Journal of Cancer 107:1481-1487, 2012 
 
18. 
PASS 15 Power Analysis and Sample Size Software. Kaysville, Utah, USA, NCSS, LLC, 2017 
 
 
 

Pro00063483:  Ph.2 Sym004 for Recurrent GBM 
Version:  07/5/2017 
 
PT-PhI-II v04.30.14 
Duke Cancer Institute 
Page 39 of 50 
CONFIDENTIAL 
 
16 APPENDICES 
16.1 
Appendix A 
 
 

Pro00063483:  Ph.2 Sym004 for Recurrent GBM 
Version:  07/5/2017 
 
PT-PhI-II v04.30.14 
Duke Cancer Institute 
Page 40 of 50 
CONFIDENTIAL 
 
16.2 
Appendix B 
 
 
 
Name: BTC Imaging SOP- Procedures for Provider Reading of MRIs and CTs 
Effective Date:  4/2012 
Review/Revision History: 
 
Definitions: 
MRI stands for magnetic resonance imaging with and/or without contrast 
CT stands for computed tomography with and/or without contrast 
Radiation therapy (RT) means treatment of the patient’s tumor with radiation 
treatment, typically for about 6 ½ weeks.  It may include stereotactic radiosurgery, which is a nonsurgical RT 
technique that delivers ionizing radiation to the tumor. Pseudoprogression means a transient increase in contrast-
enhancement on MRI without true tumor progression 
Pseudoresponse means marked decrease in contrast enhancement possibly due to anti-angiogenic therapy 
Non-enhancing disease progression means progression of the tumor with components that are 
non-enhancing on MRI 
Anti-angiogenic agents means a drug or substance inhibiting the growth of blood vessels 
Seizure means any episode, caused by abnormal electrical conduction in the brain, resulting in the abrupt 
onset of transient neurologic symptoms 
Steroids means a group of drugs that includes the corticosteroids, similar to hormones produced by the adrenal 
glands 
Immunotherapy means treatment of disease by inducing, enhancing, or suppressing an immune response 
FLAIR stands for fluid-attenuated inversion recovery [image sequences] 
RANO stands for the Response Assessment in Neuro-Oncology (RANO) 1 
 
1. 
Determine Patient Background Information 
A. Determine the patient’s medical history.  
B. Has the patient had prior surgery? 
C. Has the patient had Gliadel (carmustine) wafers placed into the resection cavity? Note: Be careful with 
therapeutic effect 
D. Has the patient undergone radiation therapy or stereotactic radiosurgery? 
Note: Be careful with pseudoprogression 
E. Has the patient taken any anti-angiogenic agents, such as bevacizumab (Avastin), sunitinib (Sutent), or 
cediranib (Recentin)? Note: Be careful with pseudoresponse and non-enhancing disease progression 
F.  Has the patient experienced seizure activity recently? 
G. Has the patient tapered up or down in their dose of steroids? H. Has the patient 
undergone any form of immunotherapy? 
 
2. 
Pick the right date of previous MRI/CT to which you want to compare the new MRI 
A. For high grade patients off therapy, go back to the MRI when they stopped 
therapy. 
B. For low grade patients off therapy, go back to baseline MRI. The best baseline MRI  is normally 2-

Pro00063483:  Ph.2 Sym004 for Recurrent GBM 
Version:  07/5/2017 
 
PT-PhI-II v04.30.14 
Duke Cancer Institute 
Page 41 of 50 
CONFIDENTIAL 
 
4 months post-operative (post-operative changes must have resolved and at the nadir of cavity 
collapse). 
C. For patients on treatment, compare to baseline (response) and to nadir 
(progression). 
 
3. 
Look at T1 pre-contrast images/non contrasted images 
A. Is there new blood? 
B. Are there calcifications? 
 
4. 
Look at T2 and/FLAIR images (Note: my preference is for FLAIR images)/non contrasted images 
A. Most frequently, we look at axial FLAIR images. 
B. Determine RANO – T2/FLAIR lesion response. 
C. Be careful with increase T2/FLAIR from tumor progression vs. treatment effect. Is there increased 
mass effect? Is there atrophy? Is it in the radiation field? 
 

Pro00063483:  Ph.2 Sym004 for Recurrent GBM 
Version:  07/5/2017 
 
PT-PhI-II v04.30.14 
Duke Cancer Institute 
Page 42 of 50 
CONFIDENTIAL 
 
 
FLAIR 
T2 
 
Response 
Definition 
Improved 
Signal abnormality decreased 
Unchanged 
Unchanged compared to prior imaging 
Worse 
Unequivocal worsening/progression of signal abnormality (due to tumor - make 
sure this is not due to infection, infarction, demyelination, radiation) 
Unable to Assess (UA) 
Unable to evaluate non-enhancing lesions because of technical factors 
 
5. 
Post contrast T1-weighted images/post contrast images 
A. Look at two planes: Axial, Coronal, Sagittal. 
B. Make sure you are looking at the post contrast scans. Is the nasal mucosa white (post 
contrast) or the same grey shade as the brain parenchyma (non contrasted)? 

Pro00063483:  Ph.2 Sym004 for Recurrent GBM 
Version:  07/5/2017 
 
PT-PhI-II v04.30.14 
Duke Cancer Institute 
Page 43 of 50 
CONFIDENTIAL 
 
 
 
T1 pre contrast 

Pro00063483:  Ph.2 Sym004 for Recurrent GBM 
Version:  07/5/2017 
 
PT-PhI-II v04.30.14 
Duke Cancer Institute 
Page 44 of 50 
CONFIDENTIAL 
 
T1 post contrast 
C. Pick target lesion. 
i.  Some lesions are followed quantitatively, some qualitatively.  
ii.  Measurable lesions are those that t you COULD follow 
quantitatively 
iii.  Target lesions are those that you WILL follow quantitatively  
iv.  Only enhancing lesions can be quantitative. 
D. Measurable lesions must have the following criteria: 
v.  Contrast enhancing 
vi.  Clearly defined, bi-dimensionally measurable margins  
vii.  Two perpendicular diameters ≥10mm 
viii.  If slice thickness + gap is >5mm, size threshold is 2 x total 
ix.  Do not include surgical cavity, cyst, or necrotic area 
E. Non-measurable lesions meet the following criteria: 
x.  Less than 1 cm in any diameter (e.g. 12 x 8 mm) 
xi.  Poorly defined margin 
xii.  Hemorrhagic or predominantly necrotic 
xiii.  Tumor around a cyst or surgical cavity, unless nodular component 
≥ 10 x 10 mm 
F.  Choosing target lesions: 
xiv.  If there is more than one, pick up to 5.  
xv.  Choose the largest lesions. 
xvi.  Should have reproducible measurement. 

Pro00063483:  Ph.2 Sym004 for Recurrent GBM 
Version:  07/5/2017 
 
PT-PhI-II v04.30.14 
Duke Cancer Institute 
Page 45 of 50 
CONFIDENTIAL 
 
 
 

Pro00063483:  Ph.2 Sym004 for Recurrent GBM 
Version:  07/5/2017 
 
PT-PhI-II v04.30.14 
Duke Cancer Institute 
Page 44 of 50 
CONFIDENTIAL 
 
 
G.  Determine RANO – Target lesion measurement/response 
i.  Axial plan is recommended, unless patient has been followed in coronals 
ii.  Pick the slice where the lesion is the largest  
iii.  Measure the longest diameter (A) 
iv.  Next, measure the greatest perpendicular diameter (B) 
v.  Calculate the target lesion size - product of the diameters (AXB) 
vi.  With multiple target lesions, calculate the sum of the product of the diameters 
(SPD) = Area001 + Area002 
vii.  Follow-up evaluation: 
a.  Measure the previously defined target lesions bi-dimensionally 
and calculate the SPD (Note: CR and PR have to be confirmed ≥4 
weeks later; otherwise, it’s just SD) 
b.  If apparent PD within 12 weeks of radiation, keep watching. If SPD stable or 
decreased on next visit, drop baseline value when picking “nadir” to compare 
against. 
c.  Are there new lesions? 
 
H. RANO – Enhancing non-target lesion response  
i.  All non-measurable lesions 
ii.  All measurable lesions beyond upper limit of 5 
iii.  All other measurable lesions not selected as target lesion 
 
Response 
Definition 
Complete Response (CR) 
All target lesions have completely disappeared. (look out for 
pseudoresponse) 
Partial Response (PR) 
SPD decreased by ≥ 50% from baseline value 
(look out for pseudoresponse) 
Stable Disease (SD) 
SPD < 50% decrease to < 25% increase 
Progressive Disease (PD) 
SPD increased by ≥ 25% from nadir value 
(smallest seen during the trial) (look out 
for pseudoprogression) 
Unable to Assess (UA) 
One or more of the target lesions cannot be evaluated 
because of technical factors 
iv.  Assessed subjectively 
 
Response 
Definition 
Complete Response (CR) 
All enhancing non-target lesions have disappeared 
completely 
Incomplete Response /Stable Disease (IR/SD) 
Enhancing lesions present, and stable or decreased in size 
compared to prior imaging 
Progressive Disease (PD) 
Unequivocal progression of enhancing lesions (see below) 

Pro00063483:  Ph.2 Sym004 for Recurrent GBM 
Version:  07/5/2017 
 
PT-PhI-II v04.30.14 
Duke Cancer Institute 
Page 45 of 50 
CONFIDENTIAL 
 
Unable to Assess (UA) 
Unable to evaluate enhancing lesions because of technical 
factors 
I. 
Pseudoresponse 
i.  Anti-angiogenic drug effects can look like response  
ii.  Apparent response may appear within 4 weeks 
iii.  This should be confirmed with follow-up imaging 4+ weeks later 
J.  Pseudoprogression 
i.  Enhancement that looks like tumor growth but isn’t  
ii.  Radiation effect can look like tumor 
iii.  Apparent PD within 12 weeks of RT 
iv.  Call it pseudoprogression (psPD) initially v.  Re-
evaluate at next imaging visit 
vi.  If further increase, call it PD on the first visit vii.  If 
stable or decreased, psPD is confirmed 
viii.  Do not consider baseline for choosing nadir – looking for 
progression 
ix.  Still use baseline when looking for response x.  New 
lesions 
xi.  PD within the 12 weeks of completion of chemoradiation can only 
be assigned if: 
a.  Majority of the new enhancement is outside of the radiation field 
OR 
b.  Pathologic confirmation of progressive disease (tricky) 
c.  Lesion continues to enlarge 
 
Baseline 
Visit 1 (8 weeks) 
Visit 2 (16 weeks) 
Visit 3 (24 weeks) 
100 
140 
psPD 
120 
SD 
150 → PD 
130 → SD 
65 → SD 
45 → PR 
K. RANO – From lesion to timepoint (radiological) 
 
Target 
Lesions 
Enhancing Non- Target 
Lesions 
FLAIR/T2 
Lesions 
New Lesions 
Radiological 
Timepoint 
Response 
CR 
CR 
Not worse 
No 
CR 
CR 
IR/SD or UA 
Not worse 
No 
PR 
PR 
Any non-PD or UA 
Not worse 
No 
PR 

Pro00063483:  Ph.2 Sym004 for Recurrent GBM 
Version:  07/5/2017 
 
PT-PhI-II v04.30.14 
Duke Cancer Institute 
Page 46 of 50 
CONFIDENTIAL 
 
SD 
Any non-PD or UA 
Not worse 
No 
SD 
UA 
Any non-PD 
Not worse 
No 
UA 
PD 
Any 
Any 
Yes/No 
PD 
Any 
PD 
Any 
Yes/No 
PD 
Any 
Any 
Any 
Yes 
PD 
Any 
Any 
Worse 
Yes/No 
PD 
NA* 
CR 
Not worse 
No 
CR 
NA* 
SD 
Not worse 
No 
SD 
NA* 
NA** 
Not worse 
No 
No Change 
NA* = No target lesions identified at baseline. 
NA** = No non-target lesions identified at baseline 
L.  RANO – Radiological and clinical factors 
 
Overall Visit 
Response 
Definition 
CR 
• 
CR by MRI 
• 
No steroids above physiological levels 
• 
Clinical status stable or improved compared to baseline 
PR 
• 
PR by MRI 
• 
Steroid dose not increased compared to baseline 
• 
Clinical status stable or improved compared to baseline 
SD 
• 
SD by MRI 
• 
Steroid dose not increased compared to baseline 
• 
Clinical status stable or improved compared to baseline 

Pro00063483:  Ph.2 Sym004 for Recurrent GBM 
Version:  07/5/2017 
 
PT-PhI-II v04.30.14 
Duke Cancer Institute 
Page 47 of 50 
CONFIDENTIAL 
 
PD 
• 
PD by MRI 
• 
Steroid dose stable or higher compared to visit at which best MRI 
response was seen 
• 
Clinical status worsened compared to either baseline or the visit which 
showed the best MRI response, and not attributable to a non tumor-
related cause 
NC 
• 
NC by MRI (possible only if no visible tumor at baseline) 
• 
Steroid dose not increased compared to baseline 
• 
Clinical status stable or improved compared to baseline 
UA 
• 
UA by MRI 
• 
Steroid dose not increased compared to baseline 
• 
Clinical status stable or improved compared to baseline 
M. RANO response criteria 
 

Pro00063483:  Ph.2 Sym004 for Recurrent GBM 
Version:  07/5/2017 
 
PT-PhI-II v04.30.14 
Duke Cancer Institute 
Page 48 of 50 
CONFIDENTIAL 
 
 
N. Additional info to help 
i.  Split lesion: measure all and add them together  
ii.  Merge: measure the big thing 
iii.  If CR by MRI but still on steroids : PR 
iv.  If PR by MRI but steroids up : SD 
v.  SD by MRI with steroids up (but neurological exam OK): SD for now 
a.  If next visit shows either neurologic or MRI worsening, call PD 
when the steroids were increased. 
vi.  For patients with non-measurable disease only at baseline: 
a.  Cannot have a CR or PR. 
b.  Best response possible is SD. 
 
Reference 
 
1.  Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, DeGroot J, Wick W, Gilbert 
MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, 
van den Bent MJ, Chang SM. Updated response assessment criteria for high-grade gliomas: Response 
Assessment in Neuro-Oncology Working Group. 28(11):1963-72; 2010.